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CHAPTER 1. GENERAL INTRODUCTION 
Thesis Organization 
This thesis is organized in alternate format and contains two studies which are presented as journal 
papers. The first paper is titled " Biocompatibility and gentamicin elution characteristics of a biodegradable 
drug delivery system for the treatment of orthopedic infection in the horse". The second paper is titled 
"Biodegradable injectable polymers for sustained antimicrobial drug release in the equine joint: An in vivo pilot 
study". Each paper contains its own summary, introduction, materials and methods, results, discussion and 
references. The literature review is designed to give a comprehensive overview and background of current 
knowledge that created the ideas to pursue these projects. The general conclusion summarizes the results of 
this project and reflects on problems, which had occurred during the study period. It also states the overall 
value and impact of this project. 
Introduction 
Septic arthritis and septic tenosynovitis are the terms used to describe a bacterial infection of a closed 
synovial cavity, either in the joint or in the tendon sheath respectively. Joint infections are devastating and 
performance limiting problems in horses that can potentially result in irreversible cartilage damage and joint 
capsule fibrosis resulting in chronic painful arthritis(l,2). In addition, chronic scarring and adhesions of tendons 
within their synovial sheaths as a result of infection may cause loss of gliding function and persistent lameness. 
To prevent chronic tissue damage, high local antibiotic concentrations are necessary to quickly 
eliminate the bacterial infection. Systemic administered antibiotics are not as effective in eliminating infection 
due to lower tissue concentrations than can be achieved by intra-articular injection, use of antimicrobial 
impregnated non-biodegradable polymethylmethacrylate (PMMA), or regional perfusion (3,4). 
The objective of our research was the development of a local drug delivery system with unique 
characteristics and benefits for an entirely new clinical approach to the treatment of musculoskeletal infection in 
the horse. Biodegradable polymers can be designed to release antimicrobial drugs at a rate and concentration to 
the target site that permits optimal therapeutic activity while reducing undesirable side effects to a minimum. 
The use of a biodegradable material for local delivery has both logistical and economic advantages. These 
materials provide a sustained high concentration of antibiotics within a synovial cavity over a period of days 
without the need for repeated intra-articular injections, and they do not require retrieval at a later date. Because 
horses have large joints, and a relatively high incidence of joint infection, they are a good model for the 
development of a local drug delivery system. Biocompatibility was an important issue in this project. 
Although a variety of biodegradable polymers have been developed, very few were designed for 
biomedical use and even fewer have been evaluated under clinically controlled conditions. Because synovial 
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structures such as joints and tendon sheaths are sensitive to exposure to foreign material, it was important to test 
the polymer for tissue reactivity. 
Literature Review 
Orthopedic Infection in the Horse 
Retrospective studies of horses with septic arthritis/tenosynovitis receiving multiple treatments 
revealed survival rates of 85% in adult horses. However, follow-up racing data show that only 56.5% of all 
horses ofracing age return to racing and only 45% of these horses are able to make more than five starts. 
Survival rates in foals are much lower. Only 45% survive to be released from the hospital( 1 ). The bacterial 
families most commonly isolated from synovial infections include Staphylococcus, Enterobacteriaceae and 
anaerobes (1). The most common organisms isolated from foals are Enterobacteriaceae(l). Culture and 
sensitivity results of previous synovial fluid samples from horses with septic arthritis, tenosynovitis and 
osteomyelitis showed good susceptibility to aminoglycosides(l,2). 
Treatment protocols include: lavage of the synovial structure with or without arthroscopic 
visualization, systemic and intra-synovial antibiotic infusion, surgical drainage with or without arthrotomy, 
partial synovectomy and non-steroidal anti-inflammatory medication(l,2). 
The benefits of anti-inflammatory medication in conjunction with antibiotics in the treatment of 
synovial infection are now better understood with the discovery of cytokine and eicosanoid pathways. 
Cytokines (eg. IL-lalpha, TNF alpha and IGF-1) and eicosanoids (eg. PGE2, TXB2 and LTB4) are very 
sensitive indicators of inflammation and they play an important role in the occurrence of damage to 
chondrocytes and synovium associated with bacterial infection(5). 
The release of lipopolysaccharide (LPS) into synovial structures from gram-negative bacteria induces 
polymorphonuclear leukocytes, chondrocytes and synovial cells to produce proteolytic enzymes such as serine 
proteinases, matrix metalloproteinases and cytokines. All of these enzymes can destroy cartilage. 
Levels of inflammatory mediators are elevated in synovial fluid of equine arthritis patients. Joint 
infection usually results in elevated concentrations ofIL-1 , IL-6, TNF-alpha and prostaglandin E2 (PGE2). 
Elevation of these same mediators occurs in in vitro models using Staph. aureus infected synoviocytes(5). 
Aggressive antibiotic treatment of a synovial infection along with the concurrent use of anti-
inflammatory medication and establishing drainage are important principles of a successful outcome. Local 
intra-synovial antibiotic injections and non-degradable antibiotic impregnated polymethylmethacrylate 
(PMMA) beads provide 10-100 fold higher antibiotic levels than can be achieved via systemic antibiotics; and 
they can significantly improve the clinical outcome (11,12,13). High local antimicrobial drug concentrations 
are achieved via intra-articular (IA) injection of gentamicin. In one study, the injection of 150 mg of gentamicin 
sulfate into the radio-carpal joint resulted in a peak mean synovial fluid concentration of 1,828 µg/ml. This 
drug level was significantly greater than that after intravenous (IV) administration alone (2.53 µg/ml), but less 
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than simultaneous IV and IA administration (5,720 µg/ml). Pharmacokinetic studies involving the release of 
gentamicin from PMMA beads produce a drug concentration of250-600 µg/ml and higher for 30-60 days at the 
site of the infection ( 16). In fact, previous studies revealed that local delivery of an antibiotic can lower the 
Minimal Inhibitory Concentration (MIC) for a non-susceptible organism, thereby making the bacteria 
susceptible to the applied antibiotic ( 16). Multiple studies in humans and dogs confirmed minimal systemic 
absorption and no nephrotoxicity ( 16, 17, 18). Local delivery systems have been used successfully in human and 
veterinary surgery in the treatment of chronic osteomyelitis, infectious arthritis and osteomyelitis associated 
with fracture repair (10,13). The impregnation of PMMA bone cement with antibiotics is routinely used in 
human and equine orthopedic surgery, and it has made a significant difference in the clinical management and 
prognosis of these patients (31, 19). 
Biodegradable Controlled Drug Delivery Systems 
General considerations 
Currently, biodegradable polymers are being developed to carry and deliver a drug to a specific tissue 
site at therapeutic concentrations while disintegrating over a pre-determined time period. This principle of drug 
delivery is designed to avoid systemic side effects including nephro-and hepatotoxicity, which are commonly 
observed with some drugs at therapeutic concentrations. 
Although most bioerodible polymers developed for biomedical use were designed for use as suture 
materials rather than for controlled release application, these materials are currently being investigated for drug 
delivery. These polymers can be prepared as various carrier systems including: macromolecular drug carriers, 
micellar systems (block copolymers composed of hydrophilic and hydrophobic segments), liposomes, 
nanoparticles and microspheres(20). Once the carrier is implanted at the tissue site for sustained drug release, 
biological mechanisms within the tissue environment, such as phagocytosis and opsonization, are triggered to 
help eliminate the carrier from the body as a natural response to foreign bodies. The character and severity of 
this response depends on the site of implantation and the nature of the polymer. The study of this response has 
developed into a separate area of material science research called biocompatibility. 
A variety of characteristics of an ideal targeting system have been established, including: 
compatibility with the body in terms of toxicity, biodegradability, and antigenicity 
protection of the drug until it reaches its site of action 
maintenance of the drug-carrier integrity until the target is reached 
avoidance of interaction with normal cells 
an ability to traverse intervening membranes 
target recognition and association 
controlled drug release to achieve the desired therapeutic effect 
carrier elimination from the body following drug release. 
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Biodegradable polymers used in drug delivery research may be classified as of natural or synthetic 
origin. Natural polymers such as collagen, gelatin, starch, cellulose and hyaluronic acid can be formulated into 
microparticles and are relatively inexpensive; however, they may cause a significant immune response due to 
their foreign protein nature. Synthetic polymers have been developed over the past 5-10 years and include a 
variety of materials including: polyglycolic acid/polylactic acid copolymers (PLGA), polycaprolactones (PCL), 
polyhydroxy-butyrate/-valerate copolymers, polyanhydrides, polyethyleneoxide/polybutylene terephthalate 
copolymers, and poly(ortho esters) (POE). 
Some of these materials degrade via bulk erosion. Bulk erosion occurs when water imbibes into the 
center of the matrix, resulting in homogenous breakdown of the polymer. This makes it difficult to achieve 
zero- order release of drugs and to control release kinetics. For instance, polyesters such as lactic acid-glycolic 
acid copolymers display bulk erosion, resulting in significant degradation in the matrix interior causing 
"dumping" of the incorporated drug into the environment(21). The drug release rate in surface-eroding systems 
is proportional to the polymer erosion rate. For surface erosion to occur, the degradation rate on the polymer 
matrix surface has to be much faster than the rate of water penetration into the matrix bulk. Ideally, the polymer 
should be hydrophobic but should also have water-labile linkages connecting monomers. Currently, only two 
polymer materials exhibit these characteristics, the polyanhydrides and their copolymers and poly(ortho esters). 
Unfortunately, two of the most widely investigated and advanced synthetic polymers in terms of the available 
toxicological and clinical data, poly lactic acid (PLA) and poly glycolic acid (PLGA), biodegrade 
homogeneously (bulk degradation) due to hydrolytic desterification of their constituent monomers. Although 
PLA and PLGA possess excellent biocompatibility and their rate ofbiodegradation can be modulated via 
copolymerization, they are not feasible for drug delivery systems where a precise and controlled mechanism of 
drug release and kinetics is required. 
Pharmacological consideration 
In addition to the polymer, the nature of the drug being incorporated into the matrix of the polymer 
also requires consideration in the early stage of the design process of a targeted delivery system. The physico-
chemical characteristics, dose, and required release pattern of a drug dictate design feasibility(22) . For 
example, insulin should be released at a constant rate most of the time, but supplemented by increases near 
mealtime to control higher glucose levels. Another example is the dosing of aminoglycosides such as 
gentamicin. Once-a-day dosing has been shown to be more efficacious and least nephrotoxic. This dosing 
regimen is based on a number ofpharmacodynamic properties including: (1) mechanism of bactericidal 
activity; (2) first-exposure adaptive resistance; (3) post-antibiotic effect (PAE), and (4) mechanism of 
aminoglycoside-induced nephrotoxicity(23 ). The post antibiotic effect (persistent suppression of bacterial 
growth following removal of the antimicrobial agent) is significantly prolonged when gentamicin is given once 
daily (6.6 mg/kg) compared with three times dosing intervals(24). In general, the higher the concentration of 
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gentamicin achieved at an infection site, the greater the bacterial killing and the greater the duration of the PAE. 
Therefore, it would be clinically desirable to have a high burst release of gentamicin once daily from the 
polymer matrix versus constant high drug concentrations. A variety of solutions are currently being investigated 
to achieve these kinetics. They include the incorporation of small magnetic beads into the polymer, which, 
when exposed to a magnetic field, increase drug release by compressing and expanding the matrix channels, 
thereby "squeezing" out more drug(25). Other approaches for achieving modulated sustained release involve 
ultrasound or enzymatic processes, and pulsatile delivery systems are being developed using thermo, 
electrically, light, pH and ionic responsive systems. 
The concentration of the antibiotic released from the polymer at the site of implantation which will 
effectively kill the microorganism, must be considered in order to be able to determine the amount of drug that 
is incorporated into the polymer. A rough estimate of the desired delivery rate (release rate [dm] as a function 
of time [dt]) may be obtained by its equivalence with the rate of drug elimination at steady state: 
dm = C1:her x CL 
dt 
where Cther and CL are the therapeutic drug concentrations in, and drug clearance from the blood circulation 
(eg. systemic treatment) or local tissue (local treatment), respectively(26). The therapeutic drug concentration 
for gentamicin is extrapolated from the Minimal Inhibitory Concentration (MIC) (see below) which is 
determined in vitro. Previous studies, which investigated the plasma and synovial fluid concentrations of 
gentamicin after the administration of 150 mg into the radio-carpal joint, revealed that mean synovial fluid 
clearance (Clb) is 1.22 ± 2.54ml/min and the apparent half-life (tal/2) is 259.2 ± 123 min. For local therapy, 
the decline in drug concentration as a function of position away from the implant site may also need to be 
considered. The total drug mass required in the polymer may then be estimated by the product of the release 
time and dm/dt, or by the integral of the release profile. 
Sensitivity of a microorganism to an antibiotic is routinely determined via antimicrobial susceptibility 
testing using the dilution or the agar disk-diffusion (Kirby Bauer) test and reveals the MIC in µg/ml in relation 
to breakpoints. Although the length of time an effective concentration of an antimicrobial must be maintained 
at the site of infection for treatment to be effective has not been determined, it has been suggested that the 
concentration in the adjacent tissues should be maintained above the MIC for 3-4 weeks(27). This would mean 
in the case of Staph. aureus, that gentamicin release from the polymer would need to maintain a concentration 
higher than 2 µg/ml, the concentration of gentamicin effective in inhibiting the growth of Staph. aureus. 
Prolonged high drug concentration and sub-inhibitory concentrations of antibiotics have also raised 
concerns regarding the development of bacterial resistance and hypersensitivity reactions. However, 
bacteriological investigations over a three year period on 544 patients with bone infection treated with 
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gentamicin-PMMA beads did not reveal an increase in the frequency ofresistant strains during this period. On 
the contrary, in several patients, a decrease in the percentage of resistance was observed(28). 
Antibiotic delivery systems for orthopedic infection 
Several biodegradable polymers including plaster ofparis, a combination of fibrin and cancellous 
bone, microspheres or sponges ofpoly(D,L-lactic-co-glycolic acid) (PLGA), the bone cement poly(propylene 
fumarate), polyanhydride, and the natural materials collagen, gelatin, and inorganic phosphates have been 
investigated recently and found effective for the delivery of antibiotics to infected bone(l 0, 15,28). A 
copolymer mixture ofpoly(lactide/glycolide) (PLG:PGA, 50:50) was used for the controlled delivery of 
gentamicin and compared with PMMA beads in a canine osteoarthritis model. A two-week gentamicin release 
was obtained, and soft tissue and bone gentamicin levels as well as microbial data indicated that the PLG-GA 
copolymer was as effective as the PMMA implants(29). Poly(L-lactic acid) based implants with I 0% 
gentamicin sulfate content, which were placed subcutaneously into the back of rats just lateral to the midline, 
have been shown to release the incorporated antibiotic throughout 30 days with a decreasing delivery rate. 
During the first 24 hours, the implants released a total amount of 3600 µg/ml gentamicin. Very good tissue 
compatibility was indicated by the absence of inflammatory cells throughout the entire time of implantation as 
shown by microscopic examination(30). As a result of their excellent biocompatibility the FDA has approved 
PLA and PLGA polymers. However, the control rate of these materials for the drug release is difficult to adjust 
and the concentrations achieved in vitro may not necessarily be the same as they are in vivo(30,37). 
Gentamicin impregnated collagen sponges (Gentacoll®• Schering-Plough, Denmark) and 
polyanhydride beads (Septacin®• Nova Pharmaceuticals Corp. Abbott-Laboratories, Chicago) have been 
commercially developed and are currently being evaluated in human clinical trials. The polyanhydride beads 
consist of a copolymer of sebacic acid and a fatty acid dimer, both naturally occurring substances. In several 
well-designed studies of experimentally induced osteomyelitis in dogs and rabbits, the efficacy of the implants 
was compared to surgical debridement alone, debridement plus placebo beads, and long-term systemic 
antibiotic therapy(32). The results of these studies revealed that the polyanhydride beads were either as 
effective or better than long-term systemic antibiotics. Microbiological examination of the implant site and 
surrounding tissue showed a significantly reduced bacterial count when compared with infection sites from 
animals, which had only received debridement as the treatment. Analysis of serum for gentamicin 
concentrations revealed that levels never failed to fall below trough concentrations throughout the study period. 
Polyanhydrides have received a considerable amount of attention because of their degradation via surface 
erosion and excellent biocompatibility. In addition, erosion rates can be programmed to last from one day to 
several years, depending on the copolymer composition. 
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Recently, a copolymer of sebacic acid (20% gentamicin) was investigated in horses for the treatment 
of septic arthritis using an in vivo model. Infection was successfully eliminated from the joint and it was 
concluded, that this copolymer may assist in the treatment of joint infection in horses(33). 
The family ofpoly(ortho esters) 
The polymer investigated in the first paper is a recently synthesized polymer of the family of 
poly(ortho esters) (POE) (25,26). Poly(ortho esters) are bioerodible hydrophobic polymers that can undergo an 
erosion process confined to the polymer-water interface known as surface erosion. A major advantage is that 
they contain acid-labile linkages in the polymer backbone so that their hydrolysis rate can be adjusted within 
wide limits by the incorporation of acidic or basic excipients(38,39,40). As water penetrates the device, the 
acidic excipient ionizes and the pH in the outer layers is lowered with consequent acceleration of hydrolysis 
rate of the acid-sensitive linkages. As a result of this process, an eroding front develops which moves into the 
device as surface erosion takes place. Biocompatibility data concerning the ultimate hydrolysis products are 
available for some of the older and newer generation POEs. An investigation of the two hydrolysis products of 
older generation POEs including 1,2,6-hexanetriol showed that they possess no significant toxicological 
hazards and that the trio! is excreted without metabolism through the kidneys(49). Hydrolysis products of 
newer generation POEs include triethylene glycol, glycolic acid, pentaerythritol, and propionic acid ®. Limited 
biocompatibility data is available for these products and are discussed below. 
The POE is synthesized under anhydrous conditions by the condensation of alkyl orthoacetate and 
1,2,6-hexanetriol(6). The use of certain triols can produce polymers that have very flexible chains, and are 
viscous pastes at room temperature even though molecular weights are in excess of 50,000 Da. These materials 
represent a unique type ofbioerodible material because therapeutic agents can be incorporated without the use 
of solvents or elevated temperatures. They are particularly well suited for the incorporation of sensitive 
molecules, which require release by zero order kinetics. 
Investigation of the POE in rats (with a gel of sodium hyaluronate (SH) used as a control because of 
its well-known biocompatibility) utilized the subcutaneous cage-implant system(42). A volume of0.5 ml POE 
was injected in a stainless steel wire cage implanted in the back of a rat at the level of the panniculus carnosa, 
and the exudate surrounding the implanted material within the cage system was collected for the quantification 
of the inflammatory components. Results revealed an initial mild inflammatory response after injection, which 
was very minimal after 14 days. Concentrations of PMNs and lymphocytes, as well as the extra- and 
intracellular activities of acid and alkaline phosphatase were not different from the controls (empty cage) and 
the SH. The total leukocyte and macrophage concentrations were higher only at seven days for both SH and 
POE compared with the control. This indicated a response in the acute phase comparable to the response 
obtained with SH. 
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The biocompatibility of the POE was investigated for the ocular delivery of 5-fluoruracil after 
glaucoma filtration surgery in people(6,43). Formation of granulation tissue is a common sequel of glaucoma 
filtration surgery. The current therapy consists of daily subconjunctival injections for up to seven days, which 
is very painful for the patient and increases the risk of side effects and infection. Sustained delivery of 5-
fluoruracil from the POE, implanted at the time of surgery, would eliminate the need for repeated injections. 
The study quantified the reaction of the anterior segment of the eye to the POE after subconjunctival injection 
in the rabbit. Sodium hyaluronate and medical grade silicone oil were used as controls. Histologic evaluation 
identified a mild eosinophilic reaction at three days after injection of the POE. The focal inflammation 
consisted of 50% eosinophils and 50% lymphocytes, densely packed with extracellular material. At ten days, 
the tissue returned to normal. Overall, there were more inflammatory cells observed than with the SH and less 
than with the silicone oil. The POE did not become encapsulated, and it degraded in a short period of time in 
vivo. No irreversible changes occurred in the tissues, indicating excellent biocompatibility. It was concluded 
that the POE showed interesting properties for use after glaucoma filtration surgery; and it deserved further 
investigation related to its in vivo release characteristics. 
Recently, a POE has been used for the development of a drug delivery system for the treatment of 
periodontal disease(44). Periodontitis is a group of dentoalveolar infections that remains one of the major 
causes of adult tooth loss. These infections are caused by a pathogenic flora established within the gingival 
sulcus. The bacterial micro flora differs significantly from that of the supragingival environment in that it 
contains more anaerobes, more gram-negative organisms, and a greater portion of motile species. Current 
treatment consists of mechanically removing supra- and subgingival plaque and calculus, followed by systemic 
or local antimicrobial agents. Tetracycline was incorporated into the POE, which released therapeutically 
effective concentrations locally within the periodontal pocket for about ten days. It was concluded that because 
polymer erosion time and rate of drug release could be readily varied, residence times and rates of tetracycline 
release could be adjusted to the requirements of a therapeutically useful system. 
The POE has also been evaluated as a biodegradable carrier of demineralized bone in the 
reconstruction oflarge diaphyseal defects in rats(40). Diaphyseal defects, resulting from trauma, infection, or 
resection of a tumor, remain a challenging problem in people. While autogenous bone is considered the best 
material for bone grafting, it may be difficult to obtain sufficient amounts of this substance, and its use requires 
an additional operation. A radial defect in rats was used as a diaphyseal segmental-defect model for the 
evaluation of material for repair. Radiographic evaluation revealed that areas of new bone were significantly 
greater in defects that had been filled with the composite of demineralized bone and POE or demineralized 
bone alone compared with those that had been filled with the POE alone. Histology confirmed these results. 
The study concluded that the POE may prove to be valuable for sustained release, because it does not inhibit 
osteogenesis, induces little inflammation, provides local homeostasis, permits molding and contouring, and is 
resorbed by four weeks. 
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In another study, the POE showed its usefulness in the delivery of the anti-inflammatory drug, 
indomethacin for the inhibition of heterotopic osteogenesis in rats. The POE/indomethacin system successfully 
prevented abnormal osteogenesis and was recommended for further investigation( 51 ). 
Biocompatibility evaluation 
The concept ofbiocompatibility is based on the interactions between a material and its biological 
environment. The failure of a biomaterial to display good biocompatibility in a clinical situation is often 
revealed by a breakdown in the desired material properties and/or an unsatisfactory clinical response(35). One 
of the most important factors in determining the biocompatibility of an implanted material is the cellular 
response to the material at the tissue-material interface. Cell-polymer interaction has mainly been investigated 
in vitro using a large variety of techniques including cell adhesion counting, cell morphology observation 
(histopathology), proliferation quantification and evaluation of cell function. 
Traditional staining techniques (H&E, van Giesen, Periodic Acid-Schiff, and avidin-biotin-horseradish 
peroxidase) may be used in the classification and identification of inflammatory cells such as macrophages, 
polymorphonuclear leukocytes (PMN), and T-and B-lymphocytes. These cell types reflect the inflammatory 
response in the presence of an implanted biomaterial within a body adjacent to the site of implantation. As a 
result of tissue damage, platelet and endothelial cell activation stimulates neutrophil and macrophage migration 
from blood vessels into damaged tissue areas . These cells may trigger the influx of other cells or may produce 
factors, which stimulate proliferation of fibroblasts, collagen synthesis and extracellular matrix formation(36). 
Processes leading to the activation and production of inflammatory cells are regulated at the molecular 
level by soluble mediators (cytokines, chemokines, and growth factors) which act through different cell surface 
specific receptors. Cytokines are a heterogeneous group of low molecular weight proteins that act locally to 
modulate inflammation and immunity. They include Interleukins 1-13 (IL-I to IL-13), granulocyte- and 
macrophage colony stimulating factors (GM and GM-CSF), and Tumor Necrosis Factor alpha and beta (TNF-
alpha and TNF-beta). Growth factors such as Transforming Growth Factor-beta (TGFbeta) and Platelet Derived 
Growth Factor (PDGF) are a group of potent hormone-like polypeptides that act as intercellular mediators(37). 
One approach to investigating the host response to a material is the use of isolated or cultured cell lines 
in vitro. Measurements of enzyme production, chemokinesis, complement and metabolic responses are useful 
for defining specific responses of tissue; however, they may have limited value in predicting the response to the 
same material in an in vivo environment. 
Immunohistochemistry has been used extensively to analyze the kinetics of the inflammatory response 
to identify the type, number and spatial distribution of cells with respect to the implant in tissue section or fluid 
(exudate). Enzyme-linked immunosorbent assays (ELISA) and radioimmunoassay (RIA) using polyclonal or 
monoclonal antibodies towards specific cell types and cytokines have become routine screening methods in 
biocompatibility assessment. 
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Translation or synthesis of any protein or glycoprotein requires the presence of corresponding 
messenger RNA (mRNA) molecules within the cell. The mRNA molecules are formed during transcription of 
the genetic information within the cell nucleus and represent the genetic information being used to make 
protein. Consequently, the analysis ofmRNA via Northern blot to determine which genes are being expressed, 
implies that the corresponding protein is being actively synthesized(38). In situ hybridization has been 
developed in order to gain more information about the cell type and location of the cells expressing specific 
genes. In situ hybridization of a labeled nucleic acid probe can be used to detect specific RNA expression 
within whole cells, and it may be applied to cytospins, frozen or fixed tissue sections(39). 
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CHAPTER 2. BIOCOMP A TIBILITY AND GENT AMICIN ELUTION CHARACTERISTICS OF A 
BIODEGRADABLE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF ORTHOPEDIC 
INFECTION IN THE HORSE 
A paper to be submitted for publication to Veterinary and Comparative Orthopaedics and Traumatology 
A.F. Sondhof, L.C. Booth, R.F. Rosenbusch, S. Mallapragada, M. Apley, C. B. Riley, and J. Heller 
Summary: 
In a preliminary study, the in vitro release kinetics ofpoly(ortho ester) (POE) impregnated with 5% 
gentamicin sulfate were determined using a double diffusion chamber with synovial fluid as the medium. 
Gentamicin concentrations were measured via fluorescent polarization immunoassay (TDx) over a 14 day 
period. The POE released gentamicin concentrations in therapeutic concentrations, however, assay- and 
sampling procedures require evaluation in further studies. 
In two separate cell culture studies the efficacy of the POE to successfully eliminate infection and the 
biocompatibility (toxicity) of the POE was evaluated using synovial and cartilage explants. Synovial membrane 
was harvested from the dorsal aspect of the radiocarpal joint of two horses and maintained in explant culture. 
Staphylococcus aureus was used to create infection in the synovial explant culture, which was then treated with 
the gentamicin-impregnated POE. Infection was eliminated after 24 hours as determined by negative culture of 
the medium. Cell function (HA) and the expression ofIL-1 and IL-6 remained at control levels after infection 
was eliminated, however, hyaluronic acid (HA) concentration gradually decreased during the following days. 
Infection was detrimental to the untreated explants. 
Poly(ortho ester) was added to synovial-and cartilage explants for five days and cell viability 
determined via the Trypan Blue method and immuno fluorescence technique (Propidium Iodide). Cell viability 
in the synovial explants was not significantly compromised by the POE; however, there was a decrease in 
viability in the cartilage explants. No detrimental effects of the POE on joint tissue were found that would 
prevent its testing in vivo. This local biodegradable drug delivery system may be a valuable aid in the treatment 
of septic musculoskeletal conditions. 
Introduction: 
Orthopedic infections in the horse, including septic arthritis, septic tenosynovitis and osteomyelitis, 
remain a serious problem that may result in irreversible cartilage damage, capsular fibrosis, intrathecal 
adhesions, pathologic fractures, and chronic lameness when infection is not rapidly eliminated from the 
synovial space(l ). Retrospective studies of horses with septic arthritis or tenosynovitis receiving several 
different treatment approaches, report survival rates of 85% in adult horses(2). However, follow-up racing data 
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show that only 56.5% of all affected horses of racing age return to racing, and only 45% of these horses are able 
to start more then five times. Survival rates in foals are much lower with only 45% surviving to be released 
following hospitalization. 
Treatment usually includes aggressive long-term antibiotic administration. Providing high drug 
concentrations at the site of infection is an essential part of an effective treatment protocol. Currently, 
antibiotic-impregnated polymethylmethacrylate (PMMA) beads or rods are the treatment of choice in horses 
and humans with established musculoskeletal infection and may significantly contribute to a successful 
outcome(3). Controlled release technology offers a novel approach to antibiotic delivery by targeting specific 
tissues with optimal therapeutic concentrations while minimizing undesirable systemic side effects. 
Biodegradable polymers are of increasing interest for a variety of therapeutic applications including their use 
for sustained drug delivery in the treatment of orthopedic infection. The use of biodegradable polymers has the 
inherent advantage over non-biodegradable alternatives such as PMMA of alleviating the need for surgical 
removal of the delivery system at a later date(3). 
The development of controlled release systems using bioerodible polymers has been significantly 
advanced over the past five years. However, biocompatibility has become an important issue with the 
introduction of these novel biomedical materials for drug delivery. Biocompatibility has been defined as the 
ability of a material to perform with an appropriate host response in a specific application, and has been 
classically described using four criteria: (I) the initial interfacial reactions (dominated by macromolecular 
absorption onto the material surface), (2) the effect of the implant on the surrounding tissue, (3) the effect of the 
tissue on the material, and (4) the systemic response to the implanted material(4). Using these criteria, an array 
of both biodegradable and nonbiodegradable polymers has been demonstrated to induce a marked inflammatory 
reaction(5). Therefore, careful selection and evaluation of the carrier material, including toxicity screening, is 
needed in the development of a polymeric material suitable for use as part of a controlled drug delivery system. 
Furthermore, a detailed understanding of the characteristics of the target tissue, the drug structure and action, 
the biologic properties of the implanted polymer, and the elimination of the carrier from the body following 
drug release is essential for achieving maximum therapeutic benefit(6). Failure of a biomaterial to display good 
biocompatibilty, particularly in a clinical situation, may result in a premature or delayed breakdown of the 
desired material properties, or an unsatisfactory biological response. 
Poly( ortho ester)s (POE) is a family of synthetic biodegradable polymers that consist of three distinct 
generations(?). They are hydrophobic polymers, which undergo an erosion process confined to the polymer-
water interface known as surface erosion. Recently, a new variation of the POE-polymers was developed, 
which is synthesized by the addition of diols to 3,9,-diethylidene-2,4,8, I O-tetraoxaspiro[5.5]undecane, where a 
glycolic acid dimer segment is incorporated into the polymer to adjust polymer erosion. 
The POE consists of a semisolid, hydrophobic and injectible form ofpoly(ortho esters) and degrades 
by surface hydrolysis. The hydrolysis process of the POE can be modulated by the addition of glycolic acid 
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dimer segments without the use of solvents, so that the residence time of the device and the rate of drug 
delivery can be controlled(?). These differences may be even more important in septic and acidic environments 
as they occur in infectious arthritis. In addition, sterilization techniques can significantly affect the mechanical 
and physical properties of PLA-PGA devices. All current standard sterilization techniques cause deformation, 
degradation, melting and softening of the polymer and result in toxic residues. In contrast, the POE can safely 
be sterilized by gamma-irradiation without toxic residues and deterioration and can be stored long-term under 
unhydrous conditions(?). 
A variety of drugs have been incorporated into members of the POE-family and therapeutically useful 
delivery systems developed including 5-fluoruracil, the narcotic antagonist naltrexone, contraceptive steroids 
such as norethindrone and levonorgestrel, and indomethacine(S,9,10). The only antimicrobial agents that have 
been investigated therapeutically so far using the POE as a carrier in a sustained release system include 
tetracycline and mitomycin C( 11 , 12). In order to determine the response of synovial and articular tissue to the 
polymer we applied a previously established in vitro model which uses changes in cell parameters including 
hyaluronic acid (HA) synthesis and cytokine production as sensitive indicators of tissue health. We 
hypothesized that, should the polymer have an undesired effect on normal cells, HA concentrations, 
histopathology scores and/or IL- I and IL-6 levels will be altered when compared with a control group. The 
objectives of the study reported here were to evaluate the biocompatibility of the POE impregnated with 
gentamicin in vitro, and to determine whether this drug delivery system could rapidly eliminate infection. 
Materials and Methods: 
Experimental design 
In a preliminary study, the elution characteristics of gentamicin sulfate from POE were studied by 
measuring the concentration of the antibiotic released from the polymer into synovial fluid into two double 
diffusion chambers over a 14-day period using an immunofluorescence (TDx) assay. Then two in vitro explant 
culture studies were conducted to evaluate the efficacy and toxic effects of the POE-gentamicin drug delivery 
system. A controlled randomized block design was used to evaluate the in vitro response of synovial and 
articular cartilage explant cultures to POE. This study was approved by the Iowa State University Animal Care 
Committee. 
Synthesis of POE 
Poly(ortho ester) was synthesized using a previously established protocol(l3). Briefly, diols were 
added to 3,9-diethylidine-2,4,8, I O-tetraoxaspiro[5 .5]undecane, where a glycolic acid dimer segment is 
incorporated into the polymer. Polymerization was done under anhydrous conditions and the solution 
concentrated on a rotovaporator with the remaining solvent removed in a vacuum oven at 40°C. The polymer 
was mixed with 5% gentamicin sulfate powde~ (1 gr equivalent to 333.33 mg of gentamicin base) and had a 
a Garacin; Schering-Plough Animal Health Corp. , Kenilworth, NJ 
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Picture 1. Double diffusion chamber for in vitro release kinetics from POE made from two 20ml 
syringes. Synovial fluid was harvested through the openings on the chamber surface. Note 
the Micropore membrane used to separate bot chambers. 
viscosity which made it possible to inject it through a 14 gauge needle using light pressure. The material was 
then sterilized in a 12 ml syringe using gamma-irradiation (2.5 mrad). 
Efficacy study - Synovial tissue exp/ant cultures 
A modification ofa previously established explant culture model was used(l4). Synovial membrane 
tissue was aseptically harvested from the dorsal aspect of the midcarpal joint of one musculo-skeletal disease-
free horse (one year of age, 345 kg body weight) within ten minutes of death, and placed in serum-free 
Dulbecco's modified Eagle's minimum essential mediuma (DMEM) supplemented with 100 IU of sodium 
penicillin/ml and 100 mg of gentamicin sulfateh/ml on ice for transportation to the laboratory. There were no 
abnormalities on clinical examination of the joint and histologic examination of a synovial tissue sample. 
Synovium was dissected from subsynovial connective tissue and fibrous capsule and sliced into 2-4 
mm2 explants (approximately 100 mg wet weight per culture well) for tissue culture. Explants were incubated 
for a total of four days in DMEM supplemented with 10% fetal calf serum without antibiotics (3 ml volume per 
well) at 37°C and 100% relative humidity in 5% C02 with daily harvesting, culture and exchange of media. 
Explants were randomly assigned to one of three groups (n=12 per group) (see Table 1). 
a Sigma Chemical Co., St. Louis, MO 
b Gentocin, Schering, Kenilworth, NJ 
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Group 1 served as a sterile, POE-free control group throughout the experiment (SC). Group 2 and 3 
explants were stabilized in culture for 24 h, and then both infected with 405 CFU/mL of a Staphylococcus 
aureus, which had been previously cultured from an infected carpal joint and frozen down at -70°C. Group 2 
served as the infected control group (SI) and group 3 (SIP) had 250 mg of POE (containing 12.5 mg gentamicin 
sulfate) added to each explant culture 18 hours post-infection. At the end of the study, all tissue explants were 
placed in 10% formalin for histologic examination. Two drops of the pooled media from each group were 
submitted for bacterial culture and the remainder stored frozen at -60°C for cytokine and hyaluronic acid 
analysis. 
Table 1. Treatment protocol for the synovial explant groups at different times after establishment of cultures. 
Group/hours 24 
CONTR (SC) Mca 
INF (SI) + S. aureus b 
INF/POLY (SIP)+ S. aureus 
42 
Mc 
Mc 
Mc+POEc 
aMedia change; bstaphylococcus aureus ; c250 mg/culture 
Toxicity study - Synovial & Cartilage exp/ant cultures 
72 
Mc 
Mc 
Mc 
96 
Mc 
Mc 
Mc 
Synovial membrane tissue was harvested from one horse (six months of age) using the same protocol 
as above. Explants were randomly assigned to one of two groups (n=l2/group): Group I served as a sterile, 
POE-free control group (SCtox). Group 2 had 250 mg of POE added to the cultures after an initial stabilization 
period of 24 h (SPtox). 
Explants were incubated for five days in DMEM supplemented with 10% fetal calf serum without 
antibiotics (3 ml volume per well) at 37°C and 100% relative humidity in 5% C02 with daily harvesting and 
exchange of media. 
Full thickness articular cartilage was excised aseptically from the metacarpo- and metatarsophalangeal 
joints of one horse (2.5 years of age) within ten minutes of death. Cartilage sections were pooled and 
maintained in sterile tubes in 30 ml serum-free maintenance medium (Dulbecco's modified Eagle medium/F 12 
DME/Fl2, suppl. with ITS+c in a 5% C02 at 37°C. After 24 h, the cartilage slices were cut into 2-3 mm3 
explant fragments , pooled, and mixed thoroughly. The cartilage was placed into preweighed, sterile, 12 x 75 
mm3 polystyrene tubesd with caps containing 2 ml of the maintenance medium. The tubes were reweighed to 
c Sigma Chemical Co., St. Louis, MO 
d Amersham Life Sciences, Buckinghamshire, UK 
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determine the wet weight of the cartilage and the weight adjusted to 100 ± 5 mg of tissue. The explants were 
allowed to stabilize in DMEM for an additional 24 hat 37°C. The chondrocyte explant cultures were then 
randomly assigned to one of two groups (n=l2) as follows: Control, polymer free group (CCtox), and a second 
group to which POE polymer was added at 24 hours (CPtox). Medium was harvested and replaced every 24 h 
for five days. Harvested media was frozen at -70°C until assayed. 
Bacterial culture of media 
Two drops of media harvested from the infected culture groups at 42 h and 72 h and from the infected 
groups which had received the polymer at 72 h and 96 h were cultured for bacterial growth on Blood agar, 
McConkey, and anaerobically. 
Hyaluronic acid concentration 
Hyaluronate (HA) in medium from synovial cultures of the efficacy study was quantified at 24 h (SC.rr 
and SP.rr groups), 42, 72 and 96 h (all groups) using a radiometric assaye in triplicate. The test utilizes 1251-
labeled HABP (hyaluronic acid binding protein) from bovine cartilage. A 100 µl sample of medium from each 
culture was pipetted into the tubes. The tubes for the standards consisted of HA concentrations at 5, 12.5, 25, 
50, 75, 100, 500, and 1000 µg/l. To each sample, 100 µl ofHABP-1251-solution was added, and the mix 
incubated for 60 minutes at 20°C. Then 100 µl of HA-Sapharose were added to each tube and the mixture 
incubated for 45 minutes at 20°C. Decanting suspension (2 ml) was then added and the tubes centrifuged for 
ten minutes at 1500 x g. Following centrifugation the tubes were decanted, the remaining moisture absorbed, 
and radioactivity measured by scintigraphy. Concentrations were determined using the standard curve. 
HA concentrations were also quantified in the synovial cultures of the toxicity study (SCtox, SPtox) 
using the same protocol. 
Histology 
At the end of the culture period in the efficacy study, synovial explants were fixed in 10% neutral 
buffered formalin, paraffin embedded, sectioned, and examined histologically using routine hematoxylin and 
eosin (H&E) staining techniques. 
Qualitative morphologic evaluation was performed using a previously established scoring system and 
evaluated by two pathologists that were masked to treatment(l5). Scores were assigned to (I) presence of 
bacteria, (2) loss of differential staining, and (3) cellular debris. 
Synovial membrane explants in the toxicity study were graded for (1) synovial hyperplasia, (2) 
subintimal edema and (3) subintimal fibrosis, (4) loss of staining and (5) debris. These variables were scored 
from 0-4 (0, normal; 1, occasional changes noted in section; 2, changes noted in approximately 50% of section; 
e Pharmacia AB, HA Test, Uppsala, Sweden 
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3, changes noted in >50 % of section; 4, changes throughout section) and the median grade for each variable 
was calculated for each of the two explant groups (SCtox and SPtox). 
Full thickness cartilage explants from the toxicity study were evaluated using H&E, Alcian Blue and 
Safranin 0 stains. Cartilage explants were similarly evaluated for (1) chondrocyte necrosis, (2) chondrone 
formation, and (3) intercellular matrix staining. The median grade for these variables were added to give an 
articular cartilage score for each section with a range from 0 (normal) to 12 (very abnormal in all 
characteristics). A cartilage explant score was then calculated for each specimen group (CCtox and CPtox). 
Viability staining of toxicity exp/ant groups 
Viability staining ofsynovial-and cartilage explants was performed in the toxicity study (n=l2/group) 
at the end of the experiment (day 5). Synovial explant viability was assessed using the Trypan Blue Exclusion 
method as previously described(l6). Briefly, each explant was rinsed in fresh DMEM without FBS before 
being placed in digestion vials and incubated with 3 ml of0.25 % trypsin-EDTA. The vials were stirred for 30 
minutes at 37°C and the explants then again rinsed in fresh culture medium three times before they were 
incubated further in 3 ml DMEM with collagenase type IVf (200 JU/ml ofDMEM media) for 20 minutes at 
37°C. The filtrate from the base of the digestion vial was collected and centrifuged for two minutes at 6500 g. 
The centrifugation pellet was placed on a glass slide and 30 µl of 0.1 % trypan blueg in PBS solution was 
added. Two hundred cells were immediately counted and the viability calculated as a percentage of unstained 
cells (stained cells and unstained cells) x I 00. 
Cartilage explant viability was performed using fluorescence microscopy. Explants were rinsed three 
times in fresh DMEM and a 2-3 mm2 piece of cartilage from each explant group was mounted on the tissue 
stage of a Microslicerh with 0.1 mol PBS as the buffer solution. The articular surface was sectioned into 70-
100 µm slices and immediately placed on a glass slide. Two drops of Mounting Medium with propidium 
iodidei were added to the tissue slice and examined at 1 OX magnification under a fluorescence microscopei. 
Photomicrographs were taken from each section with and without fluorescence light. Because the cartilage 
thickness and cell density varied, cell viability was determined via image analysis counting the number of 
fluorescing dead (yellow) cells per unit area (mm3) on a photomicrograph compared with the same unit area of 
a photomicrograph without a fluorescence filter (all cells). 
f Sigma Chemical Co., St. Louis, MO 
g Sigma Chemical Co., St. Louis, MO 
h DTK I 000, Pelco, Tustin, CA 
i Vectashield® H-100, Vector Laboratories, Burlingame, CA 
j Olympus BX 60/BX-FLA, Sun Valley, CA 
21 
Cytokine expression 
Samples of previously harvested culture media in the efficacy study were thawed and assayed for IL-
1 beta and IL-6 using commercially available ELISA kitsk. These assays employ the quantitative sandwich 
enzyme immunoassay technique with monoclonal antibodies specific for recombinant human cytokines pre-
coated onto a microtiter plate. The sensitivity for these assays has been determined to be less than 1 pg/mL and 
less then 0.7 pg/mL for IL-1 and IL-6, respectively. 
Media from all groups of the toxicity study (SCt0 x, SPtox, CCt0 x, CPtox) was also assayed for IL-
1 beta and IL-6. 
Cytokine concentrations were expressed as a ratio to the baseline value for each synovial explant 
treatment group. 
Data Analysis 
Data for all variables was averaged and expressed as a mean ±SEM. For synovial explants, the 
toxicity portion of the experiment (SC vs SP) was evaluated separately from the efficacy portion of the 
experiment (SC vs SI and SIP). Values were compared by 2 way-ANOVA with repeated measures. Where 
significant differences were identified, post-hoc comparisons were made using Sheffe's test and significance 
recognized for values of P<0.05. 
Results: 
In vitro gentamicin release (chamber & cultures) 
The release of gentamicin from the polymer (500 mg) into the two diffusion chambers at 12 and 24 hours 
averaged 105.5 µg/ml and 202 µg/ml, respectively. During the following 24 ha high release of gentamicin 
measured 3830 µg/mL from the POE, which was followed by a plateau of sustained release for the following 13 
days averaging 4269.23 µg/mL per day. The highest drug concentration was measured at 96 h with 6500 
µg/mL. The polymer visibly degraded and dissolved within the synovial fluid over a 4-5 day period; however, 
high gentamicin levels were maintained throughout the study period. The release of gentamicin in the 
synoviocyte and cartilage cultures was fairly similar during the study period with 2475 µg/mL and 158 l µg/mL 
at six hours and 3420 µg/mL and 3360 µg/mL at 24 hours, respectively. No gentamicin levels were found in 
the media prior to adding the polymer at 18 hours. 
Subjectively, the polymer material appeared to disintegrate and dissolve slightly faster in the cultures 
compared with the degradation within the synovial fluid chamber. This was particularly distinct in the synovial 
explants when compared with the cartilage explants. 
k Quantikine, R&D Systems, Minneapolis, MN 
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Hyaluronan synthesis 
The mean hyaluronan concentrations from the SC group did not differ significantly from that of the SP 
group over a 72 h time period. However, there was a time effect with HA values found to be significantly 
higher at 24 h than 42 h or 72 h (P<0.05). For subsequent comparisons among SI and SIP groups, SC and SP 
values were pooled as controls (SCP). The mean HA values of the control group was significantly greater than 
values for the SI and SIP groups (P<0.00 I), and mean SIP values were significantly greater than mean SI 
values (P<0.001). Significant differences in values between 42 hand 96 h were also found (P<0.01). This 
decline in HA concentration was most apparent in the SI group after 18 h of exposure to S. aureus. The 
concentration of HA in the SIP group was similar to the levels in the control group at 42 hours, but significantly 
declined during the remainder of the culture period. 
Hyaluronan concentrations in the toxicity study were not significantly different between SCtox and 
SPtox, however, there was a statistically significant difference present between the two cartilage groups (CCtox 
and CPtox). HA concentration had significantly declined in the CPtox group after 48 hours of incubation with 
the POE. 
Figure 1. HA concentrations in the synovial explant efficacy study. Note the very low HA 
concentration in the infected and untreated group at 42 hours. HA concentration in the 
infected and POE treated group reached almost control levels. 
23 
IL-theta and IL-6 
Apparent differences in IL-1 beta and IL-6 levels among synovial explant groups in the efficacy study 
were not statistically significant. There was a trend for increased expression of IL- I beta in the SI group at 42 
hours and an increase of IL- I beta in the SIP group. However, cytokine levels declined significantly over time 
(P<0.05). lnterleukin-6 showed an increased expression from the baseline in the SI group compared with the SP 
and SIP groups. 
No difference between IL- I beta and IL-6 expression was found among the synovial explants in the 
toxicity study, but we observed an increased expression ofIL-lbeta and IL-6 in the cartilage explant group 
(CPtox) after the POE had been added for 24 hours. 
Histology and Viability staining 
All synovial and full thickness cartilage samples harvested were histologically normal prior to tissue 
culture. 
Histopathology scores for the SC group in the efficacy study remained low except that the score for 
bacterial presence was almost as high as in the infected group. Scores for the SI group were significantly 
higher compared with SC and SIP. Scores between SC and SIP were not significantly different (p <0.05), but 
SIP had a lower score for bacterial presence. 
Synovial explant viability staining was >80% in the control groups of the toxicity study. Groups 
which had the polymer added showed a viability of>90%. Histopathology scores of the control group and the 
group, which had POE added, were not significantly different (p <0.05). However, there was a significant 
difference among the cartilage groups concerning cell viability and histopathology scores. Viability in the 
control group (CCtox) reached 245 cells/unit area compared with 98 cells/unit area in the CPtox group. 
Histopathology scores were higher in the CPtox group. Chondrocyte necrosis was present in 50% of 
the explants with fibrillar matrices and patchy eosinophilic stains. 
Microbiology (Culture of Media) 
All groups, which were intentionally infected with a S. aureus cultured positive at all times. The SIP 
group was negative for S. aureus 24 h after addition of the polymer. All other groups including the explants 
from the toxicity study cultured negative for bacteria at all times. 
Discussion: 
We evaluated the material under in vitro conditions to gain basic data concerning the effects of the 
material on joint tissue. This allows estimation of the response that can be expected when the polymer is 
injected into a synovial cavity in vivo and ultimately determines whether this polymer is suitable for controlled 
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drug release in the joint. Also, we used fairly young animals for our explants because we considered juvenile 
tissue to be more sensitive and amplify any cellular insult that may result from the presence of the polymer. 
The POE was chosen for the development of a controlled drug release system because previous studies 
have indicated excellent biocompatibility. In recent studies involving second generation poly(ortho esters), it 
was found that the two ultimate hydrolysis products possess no significant toxicological hazards and are 
excreted without metabolism through the kidneys( 17). The addition of polymer to synovial membrane explants 
did not result in significant changes of cell parameters including HA-synthesis and cytokine production. 
Hyaluronan concentration remained at high levels at all times in the SC and SP groups. Histopathology scores 
were not significantly different from scores from the control groups, which may indicate that the breakdown 
products during polymer degradation do not cause harmful or compromising effects on synovium. 
The gentamicin release from the POE eliminated infection from the synovial explants and significantly 
reduced bacteria counts compared with the SI group. However, the relatively high bacteria score in the control 
group precluded distinguishing more between the SIP group and the control group. Possible reasons for this 
may be contamination at the time of harvesting the synovial membrane or during and after the culture process. 
The most likely reason for the bacterial presence in the culture may be that bacteria were introduced during 
processing, because no significant morphologic cell changes were observed at the end of the culture period and 
HA concentration remained at high levels at all times. The increased expression of IL-1 at 96 hours in the 
control group may further support a late introduction of the bacteria. 
Histopathology scores in the SIP group almost reached levels of the SC group after POE was added to 
the previously infected synovial explants. Although HA-concentration reached control levels after infection 
had been eliminated, we observed significant deterioration of HA-synthesis at 72 hours in the SIP group. This 
may be either the result of decreased synthesis or increased degradation of HA by bacterial hyaluronidase. 
Because we did not evaluate cell viability in this group, it is possible that cell death may have been the cause 
for the decreased HA concentration. However, HA concentration remained at normal levels after elimination of 
infection, which makes acute cell death as a cause more unlikely. Lower HA concentrations have been found in 
septic joints and have also previously been reported in an in vitro synovial explant infection model( 18, 19). 
Hardy et al. ( 1998) reported that filtered media from previously infected synovial cell cultures added to 
synovial explants caused inflammatory mediators to raise and HA concentrations to fall . When filtered media 
was added to cartilage explants, matrix degradation occurred. 
Cook et al.(14) found that HA concentrations in infected synovial explants were dramatically 
decreased after infection had been eliminated with a biodegradable drug delivery system. Even though 
infection is rapidly eliminated from joint tissue, ongoing deterioration of cells may account for the low HA 
levels. It has been suggested that decreased HA synthetic rate, rather than increased degradation may be the 
mechanism for decreased HA concentration in culture medium(l 8). Our results confirm these findings, 
although HA concentrations in our explants temporarily reached control levels. 
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Cartilage explants responded very differently to the POE. Histopathology scores in the CPtox group 
were significantly higher compared with the control group. Saffranin 0 staining indicated that most of the 
proteoglycan had been washed out from the extracellular matrix. Why the scores are so much different from 
the synovial explant can only be speculated. Although one may expect a more dramatic response by the 
synovium as synoviocytes commonly are the first line of defense in injury, chondrocytes appear to be more 
sensitive in this case. This, however, was not reflected by an increase in cytokine levels in the cartilage 
explants, which may be a result of matrix damage, but not damage to the nucleus. By using smaller amounts of 
the POE, this response may be alleviated. However, only in vivo testing may reveal whether or not this is a 
significant finding. Future in vivo studies with the POE need to include the evaluation of glycosaminoglycan, 
chondroitin sulfate, or keratan sulfate concentrations of cartilage specimens. 
Immunohistochemistry is being used extensively in the assessment of biocompatibility of biomedical 
implants. Immunohistochemistry has also been a valuable tool in the investigation of joint disease and serves 
as a sensitive indicator for saddle changes in the normal environment of synovium and cartilage in the joint. 
We assumed that any detrimental effects of the polymer on synoviocytes and cartilage would be expressed as 
an increase in certain inflammatory mediators including cytokines. This model focused on the expression of 
IL-1 and IL-6 because they have been consistently found to be released in medium and synovial fluid by 
synovial cells as a response to injury. IL-1 is a key mediator of the inflammatory host response to microbial 
invasion and contributes to the destruction of cartilage(20,21 ). Both equine mononuclear cell factor (MCF) and 
recombinant huIL-1, alpha and beta, have been shown to stimulate the production of PGE2 by equine 
chondrocytes and synovial cells in vitro and inhibit proteoglycan synthesis in equine articular cartilage(22). 
We used human ELISA test kits because hybridization studies of human, murine and equine IL-1 revealed high 
homology among them(23,24). 
At no time did the presence of the polymer in the synovial explants cause an increase in cytokine 
levels compared with the control groups. Our other results of this study concerning IL-1 and IL-6 production 
differ in some aspects from previous studies. There was an increase in IL- I expression in the infected group, 
which had been treated with the POE. This may reflect a post-infectious rebound-response of the synoviocytes 
after the invading pathogen has been eradicated from the system. It has been documented that synovium and 
cartilage are undergoing continuous degenerative matrix changes even though the infection has been 
eliminated. These ongoing changes have been associated with the sustained synthesis of inflammatory 
mediators such as IL-1 by synoviocytes and have been referred to as "post-infectious arthritis"(25). In a 
previous synovial explant study using S. aureus to infect the synoviocytes, it was found that IL-1 beta 
concentration ratio remained significantly high in groups which had received bacteria-free (filtered) media from 
previously infected synovial explants, even after culture was continued with standard medium(18). We did not 
observe the early increase in IL-1 after S. aureus infection that has been seen in previous studies, which may be 
related to the dose of antimicrobial exposure. Although the amount of bacteria (405 CFU/mL) that was added 
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to the explants for infection has been shown to result in sufficient cellular damage without causing cell death, 
our explants may have become more compromised by the amount of bacteria making them unable to respond. 
The fact that HA-concentrations were significantly decreased in this group may indicate a detrimental insult to 
the cells that might have led to cell death. On the contrary, when S. aureus was added to the SIP group and 
infection was eliminated with the POE, cells retained the ability to synthesize HA, which indicates normal cell 
function. 
Interleukin- I is a potent inducer of IL-6, which is also produced by synovial cells(26). Although there 
was a trend in the SI group for increased expression of IL- I, the expression of IL-6 was more significant in the 
same group at the same time. Assuming, that IL-6 typically shows a delayed appearance, which is stimulated 
by IL-I or TNF, then our data would suggest that IL-I beta may have become elevated shortly after infection to 
cause IL-6 to raise later on. 
The overall good biocompatibility of the POE in this culture model is consistent with data from other 
groups(27). Bernatchez et al. found that subconjunctival injection of the POE caused a mild eosinophilic 
inflammatory response at injection sites in laboratory animals when compared with sodium hyaluronate and 
silicone oil. The acute inflammation resolved completely by day ten and no encapsulation with fibrous tissue 
occurred. However, these in vitro results concerning the tissue response towards the POE may not necessarily 
correlate with the response in an in vivo environment and therefore need to be interpreted carefully when 
extrapolated to injection of a joint. Although the hydrolysis products of the POE including triethylene glycol, 
glycolic acid, pentaerythritol and propionic acid have not been associated with toxicological effects in 
laboratory animals, injection of the POE into a synovial structure in the horse may result in undesired site 
effects. 
The release of gentamicin from the POE in our preliminary kinetic study occurred in a burst during 
the first 24 hours; however, the drug release during the next 13 days was more characterized by a high 
sustained release of gentamicin. This phenomena has been well recognized in the synthesis of polymers and 
constitutes one of the greatest problems in the design of controlled drug delivery systems. "Dumping" of the 
incorporated drug may lead to undesired toxicity of the drug and makes the release kinetics much more random. 
Ideally, the main mechanism responsible for the release of drug from a biodegradable polymer is surface 
erosion while the drug is uniformly distributed through the polymer facilitating zero-kinetic release(28). In 
order to obtain zero-order release, a geometry may be necessary that does not change its surface area as a 
function oftime(29). Bulk erosion in addition to surface erosion, as seen in both the kinetic- and the culture 
study, is a result of the polymer imbibing water into the center of the matrix and has been observed with other 
polymers as well. Polylactic acid (PLG) and polyglycolic acid (PLGA) polymers used for biomedical 
application are well known for this problem which makes the controlled release in these materials particularly 
difficult(30,3 l ). We also accounted some problems with the diffusion chamber set up. While we were using a 
500 mg POE sample which had a total amount of25 mg gentamicin incorporated for release, the total amount 
27 
of gentamicin that was found in the synovial fluid over the entire time period added up to approximately 80 mg. 
This discrepancy may be the result of an invalid assay procedure. While the immunofluorescence assay (TDx) 
is routinely being used to determine gentamicin levels in serum this assay is not validated for the measurement 
of drug levels in synovial fluid. For that reason, a different technique may need to be applied such as High 
Performance Liquid Chromatography (HPLC) in order to get accurate drug concentrations. 
One of the significant advantages of the POE over other polymers is that the release of drugs from this 
polymer matrix can be predictably controlled and adjusted by varying the concentration of glycolic acid dimers. 
For future studies with the POE, particularly in vivo, the release of drug during the first 24 hours needs to be 
adjusted to a more homogenous system in which high drug concentrations are reached fast and then maintained 
at that level for the desired period of time. Gentamicin was chosen to incorporate into the polymer, because of 
its broad gram-negative spectrum and efficacy for the most commonly cultured organisms found in infected 
joints(2). Previously reported susceptibility patterns for these organisms have not differed from findings in our 
hospital. However, from a pharmacokinetic point of view, aminoglycosides may not be the drug of choice for 
sustained release because of their significantly increased efficacy when administered once daily at a high dose. 
Once-a-day dosing prolongs the "post-antibiotic effect" and has been associated with the least potential for 
nephrotoxicity. Therefore, it may be clinically more beneficial to release gentamicin in a "pulsatile" fashion , 
which is currently being investigated in stimuli-responsive ("intelligent") delivery systems(32,33). 
Pharmacokinetic studies commonly use buffer systems such as PBS (pH 7.3, 154 mmoVL) to 
determine the concentrations of drugs released into a closed system(34). We used synovial fluid because we 
assumed that the release into an environment such as the joint may be different from the release into a 
phosphate buffered saline environment. Several factors may significantly influence the release of drug as a 
function of time, particularly when considering microparticles (microspheres) and ointments as the drug carrier 
matrix. These may include differences in viscosity of the fluid surrounding the polymer and the difference in 
the composition of the fluid. Synovial fluid is an ultrafiltrate of plasma and contains ions and molecules such 
as hyaluronan in high concentrations (0.5 mg/ml)(35). It is unknown at this time how these factors influence 
the release of drug into the environment and which impact they have on the polymer matrix itself. By using 
previously harvested normal synovial fluid as the medium from horses unaffected by joint disease, we 
attempted to simulate in vivo conditions, which would give us a more realistic idea about the release from inside 
a closed synovial cavity. 
In summary, the POE was able to effectively eliminate infection from a synovial explant culture. 
Although HA-synthesis was maintained during and after the infection, HA-concentrations significantly declined 
shortly post-infection. POE did not cause an increase in cytokine levels in the synovial explant groups and 
remained within control-levels or below. The gentamicin-impregnated polymer did not decrease synovial 
explant viability, however, cartilage explants showed a moderate decline in viability and some significant histo-
pathologic changes after five days of exposure to gentamicin-impregnated POE. 
Picture 2. 
Picture 3. 
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Photomicrograph (lOx) of cartilage explants. Left: Explant with POE added for five days. 
Right: Control explant. Note the pyknotic and karyorrhectic chondrocytes. 
Photomicrographs of synovial explant (lOx magnification). Left: infected and POE treated 
synovial explant. Right: infected untreated explant. Note bacteria on surfaces and in 
subintimal tissues. 
29 
Our data did not reveal any detrimental effects of the POE on joint tissue that would prevent its testing 
in vivo. Because polymer erosion time and rate of drug release can be readily varied for this material, residence 
times and rates of gentamicin release may be adjusted to the requirements of a therapeutically useful system. 
The material may be a valuable adjunct therapy in the treatment and prophylaxis of septic musculoskeletal 
conditions in the horse. 
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CHAPTER 3. BIODEGRADABLE INJECTABLE POLYMERS FOR SUSTAINED 
ANTIMICROBIAL DRUG RELEASE IN THE EQUINE JOINT: 
AN IN VIVO PILOT STUDY 
A paper to be submitted to Veterinary and Comparative Orthopaedics and Traumatology 
A. F. Sondhof, S. Mallapragada, L. C. Booth, C. Heath, W. Hsu, R.F. Rosenbusch, M. Apley, Heller J 
Summary: 
Microspheres consisting ofpoly(DL-lactide-co-glycolide) (PLGA) and poly(e-caprolactone) (PCL) 
were prepared via double emulsion technique and impregnated with 15% gentamicin. The gentamicin release 
from both polymers into double diffusion chambers filled with synovial fluid were evaluated over an eight day 
period via a radioimmunoassay. Release of gentamicin from PLGA and PCL measured 2.05 µg/ml and 40.4 
µg/ml at 12 hours, respectively. Synovial fluid samples from both polymers inhibited the growth of a S. 
aureus in vitro. 
The articular response to PLGA microspheres injected into the radio-carpal joint of three horses was 
compared with the injection of another polymer, Poly ( ortho ester) (POE) ointment which was injected into the 
tibio-tarsaljoint of three horses over a 4 day period. Biocompatibility data revealed a mean WBC of28,945 
cells/µL and 91% mildly degenerated neutrophils in the PLGA-injectedjoints versus 3,528 cells/µL and 90% 
neutrophils in the POE injected joint. 
Protein levels, lymphocyte and macrophage counts were also elevated. Total cell count in the injected 
joints reached control levels after 96 hours. None of the horses showed significant clinical signs from the 
PLGA or POE injection. Although both polymers POE and PLGA cause a short-term moderate synovitis and 
may be suitable as a biodegradable drug delivery carrier in the equine joint, the POE seems to cause less 
irritation of the synovial membrane. Because in vitro drug release from the PCL polymer was promising based 
on the levels of drug eluting, PCL deserves further evaluation for drug delivery in the equine joint. 
Introduction: 
Septic arthritis is a disorder that results from sequestration of bacteria in a joint. The cause of septic 
arthritis can be (1) hematogenous in origin which is common in foals but rare in adults; (2) spread from an 
adjacent infected soft-tissue focus; (3) occur as the result from a penetrating wound; or (4) occur secondary to 
surgery (eg. arthroscopy). Other sources for joint infection in the adult horse are inoculation during intra-
articular injection and open fractures, which are extending into joint cavities. The incidence in foals on 
breeding farms has been reported to be 1 %, but causes mortality in 0.25%(1 ). The risk of infection was the 
highest in the first 30 days. Polyarthritis is common in foals (50% of those with infectious arthritis) and 
uncommon in adults (1.5%) (2). 
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Although therapy selection including a combination of antimicrobial and joint drainage protocols has 
significantly improved the prognosis and mortality rate, septic arthritis remains one of the most detrimental and 
performance limiting injuries in the horse industry. This is in part due to severe and chronic damage to the 
synovial structures which is triggered by the induction of an inflammatory process by the invading 
microorganism. 
A significant contributing factor to the development of traumatic infection is extensive soft-tissue 
damage that causes disruption of blood supply and lymphatic drainage as well as compromising local immune 
response against initial contamination (3). This results in low antimicrobial tissue levels at the site of infection 
when antibiotics are administered systemically. To provide therapeutic antimicrobial drug concentrations, local 
delivery has become an important adjunct therapy in the treatment and prophylaxis of musculoskeletal 
infection. Implantation of antimicrobial-impregnated polymethylmethacrylate (PMMA) beads into a site of 
infection has been an effective method for providing sustained high concentrations of antibiotics locally. 
PMMA beads are currently recommended for use in the treatment of open fractures and acute and chronic bone 
and joint infections. However, removal of the beads from immobilized joints after elimination of the infection 
can be difficult due to granulation tissue or fibrous scar tissue formed around the beads. To overcome this 
disadvantage, biodegradable materials have been used to carry and release antimicrobial drugs over a sustained 
period of time. Some of the first materials investigated for this purpose were poly(lactic acid) (PLG) and 
poly(glycolic acid) (PLGA) polymers and their copolymers, because they display important advantages of 
biocompatibility, predictability ofbiodegradation kinetics, ease of fabrication, and regulatory approval by the 
FDA. Importantly, these polymers can be purchased commercially. Biocompatibility as well as biodegradation 
rate of PLG and PLGA polymers depends on their components and molecular weight, respectively. Other 
influential factors include the repeat structure of the copolymer, the pH and ionic strength of the external 
medium, and the nature of the drug incorporated into the delivery device. 
However, biocompatibility of PLA and PGA is still somewhat controversial and the majority of 
available data is from laboratory animals or has been established using cell culture systems. Extensive 
experimental and clinical data support good tissue receptivity by implantation in bone. Cutright et al. ( 19) 
investigated different polymers and copolymers of PLA and PLG in rat femurs and in the mandible of rhesus 
monkeys. They found that the polymers were replaced by connective tissue, bone and marrow tissue, thus, 
suggesting good biocompatibility. In contrast, non-specific foreign-body reactions with osteolysis has been 
reported once degradation of the PLA began(l8). To our knowledge, there is currently no data available on the 
use of PLG microspheres within synovial membrane cavities in companion animals. 
Poly( ortho ester) consists of a semisolid, hydrophobic and injectible form and degrades by surface 
hydrolysis. The hydrolysis process of the POE can be modulated by the addition of glycolic acid dimer 
segments without the use of solvents, so that the residence time of the device and the rate of drug delivery can 
be controlled(?). These differences may be even more important in septic and acidic environments as they 
35 
occur in infectious arthritis. The POE can safely be sterilized by gamma-irradiation without toxic residues and 
deterioration and can be stored long-tenn under unhydrous conditions(?). In contrast, sterilization techniques 
can significantly affect the mechanical and physical properties of PLA-PGA devices due to defonnation, 
degradation, melting and softening of the polymer and may result in toxic residues. 
To our knowledge, Poly(ortho ester) has not been investigated for the use of controlled drug delivery 
in companion animals. Only limited data concerning the biocompatibility have been reported including rat 
studies investigating POEs for ocular delivery of 5-fluoruracil after glaucoma filtration surgery in people. The 
POE was compared with HA and medical grade silicone oil. POE has recently been investigated for the use in 
the treatment of orthopedic infection in the horse. Cell culture studies have shown that gentamicin impregnated 
POE can successfully resolve a Staph. aureus infection of synovial membrane (20). However, a 250 mg sample 
of the POE, which was added to synovial, explants and cartilage explants, revealed that cartilage may be more 
sensitive to the material than synovium as indicated by viability staining. It was concluded that POE may be a 
valuable aid in the treatment of orthopedic infection. In vivo data may be needed to ultimately detennine the 
biocompatibility. 
The purpose of our study was (I) to detennine the in vitro elution kinetics of gentamicin in synovial 
fluid from 50150 drug loaded poly(DL-lactide-co-glycolide) (PLGA) microspheres which was compared with 
the gentamicin elution characteristics ofpoly(e-caprolactone) (PCL) which is another commonly used polymer 
for drug delivery, and (2) to establish biocompatibility data of two polymers (PLGA and POE) after injection 
into joints of horses. 
Materials and Methods: 
Preparation of polymers 
50150 poly(DL-lactide-co-glycolide)a and poly(e-caprolactone)b microspheres of 80-120 µm diameter 
in size impregnated with 15% of gentamicin sulfatec were prepared via the double- emulsion-evaporation 
technique as previously described(12). The size of the microspheres were detennined via a microscope and 
sterilized using ethylene-oxide. 
Poly(ortho ester) was synthesized using a previously established protocol(13). Briefly, diols were 
added to 3,9-diethylidine-2,4,8, I O-tetraoxaspiro[5 .5]undecane, where a glycolic acid dimer segment is 
incorporated into the polymer. Polymerization was done under anhydrous conditions and the solution 
concentrated on a rotovaporator with the remaining solvent removed in a vacuum oven at 40°C. The polymer 
was mixed with 5% gentamicin sulfate powder<' (I gr equivalent to 333.33 mg of gentamicin base) and had a 
a Binningham Polymers, Inc., Binningham, AL 
b Binningham Polymers, Inc., Binningham, AL 
c Gentocin, Schering Corp, Kenilworth, NJ 
d Garacin, Schering-Plough Animal Health Corp., Kenilworth, NJ 
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viscosity which made it possible to inject it through a 14 gauge needle using light pressure. The material was 
then sterilized in a 12 ml syringe using gamma-irradiation (2.5 mrad). 
In vitro release kinetics 
The in vitro release was assessed with the use of a double diffusion chamber separated by a Millipore 
membranee. The donor side contained 50 mg microspheres diluted in a 5 mL saline solution and the receiver 
side only synovial fluid (15 mL volume). The chamber was continuously agitated and samples of synovial 
fluid (I ml) from the receiver side collected and replaced with fresh synovial fluid over a ten day period. 
Synovial fluid was assayed in duplicates using a radioimmunoassayf. 
Documentation of Gentamicin Bioactivity 
Aliquots of the harvested synovial fluid samples from the above study were also tested for bioactivity 
against a lawn of S. aureus. A virulent S. aureus isolate from an infected equine joint was kept frozen at -70°C 
for use in this study. A suspension matching a 0.5 McFarland turbidity standard was prepared and used to 
create lawns of S. aureus on Mueller Hinton agar plates. Six mm holes were punched into the agar using a 
disposable biopsy punchg and filled with 100 µL synovial fluid collected at days 1, 3, 5, 8 and 10. There were 
three holes/plate which were incubated for 24 hours at 3 7°C and then the zone of inhibition was measured. 
In vivo preparation 
Six horses (two 18 years of age) were divided into two groups, a PLGA and a POE group, of three 
horses each. The study involving the PLGA group was performed first to gain basic knowledge about catheter 
placement and joint response towards the polymer. Because problems with the maintenance of the catheter 
were experienced, a larger joint -the tibio tarsal joint- was chosen for the POE group. This facilitated 
arthrocentesis and consistently provided adequate amounts of synovial fluid . 
Horses of both sexes and various breeds with no prior history of joint disease were used. Each horse 
was judged to have clinically normal antebrachiocarpal- and tibio tarsal joints if effusion, heat, or signs of pain 
on palpation were lacking. In addition, all horses were considered sound if no lameness was observed when 
trotted in a straight line. The Iowa State University Animal Care Committee approved this study. 
In the PLGA group, the left and right radio-carpal joint of three normal horses were aseptically 
prepared. One antebrachiocarpal joint (left) was chosen for treatment in each horse before the experiment. A 
catheterh (2.5 cm long, 0.8 mm in diameter) was aseptically introduced into each joint at the palmarolateral 
e Type NY60, Millipore Corporation, Bedford, MA 
f GammaCoatrM, Incstar Corp., Stillwater, MN. 
g Disposable Biopsy Punch, 6 mm, Premier. 
h Angiocath, The Deseret Co., Sandy, UT 
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pouch as described( 17). Synovial fluid specimen (0.4 ml) was obtained through the catheter. The catheter was 
removed after 36 hours and sample collection was continued via arthrocentesis using aseptic technique. 
A 200 mg polymer sample was dissolved in 4.85 mL H10, 0.05 mL Tween soc, and 0.1 mL 2% 
CarboxymethylcelluloseC and injected under aseptic conditions into one antebrachiocarpal joints of each horse. 
In the POE group, a 4 gram sample of self-catalyzed ointment was injected under sterile conditions 
using a I 0 ga I Y2 inch needle into the right tibio-tarsal joint in each horse. The opposite joint served as the 
control and was sham-injected with 5 ml of sterile saline. Synovial fluid collection was performed via 
arthrocentesis. 
A synovial fluid sample was collected from all joints prior to polymer injection for cytology. 
Synovial fluid cytologic examination 
Synovial fluid specimens for cytologic examination were obtained in both groups using a I ml 
tuberculin syringe and a 2.5 cm long, 0.8 mm in diameter hypodermic needle, at post-injection hours (PIH) 24, 
48, 72, and 96. To prevent clot formation, the specimens were transferred immediately to tubesi (2 ml) 
containing the di sodium salt of edetate. Smears for the differential leukocyte count were made immediately. 
Specimens were refrigerated at 4°C and were evaluated within 24 hours of collection for color and 
transparency, and pH. Refractive indexj was measured principally to estimate fluid total protein concentration. 
White blood cell countsk (WBC) and neutrophils, large mononuclear, as well as small mononuclear cells were 
quantitated by examination of Wright-stained smears. 
Synovial fluid gentamicin concentration 
Gentamicin levels in the collected samples from the POE- and the PLGA group were quantified using 
an automated fluorescence polarization Immunoassay (FPIA) analyzer1• Hyaluronidase Jyophilized desiccatem 
was added to each sample to decrease the viscosity of the synovial fluid for analysis by the TDx-analyzer. 
Clinical evaluation 
All parameters were assessed prior to polymer injection and daily prior to synovial fluid collection 
throughout the study period and until three days after the last collection. Parameters included joint 
circumference, carpal flexion, and degree of lameness. Lameness was graded using a scale from 0 to 5. (0 =no 
lameness at a walk or trot; I = no lameness at a walk, alterations of gait at a trot; 2 = alteration of gait at a walk, 
head bob at a trot; 3 = obvious head bob at a walk or trot; 4 = intermittent non-weight bearing; 5 = persistent 
1 Sterile blood collection tubes, Monoject, St. Louis, MO 
j Total solids meter, American Optical Corp., Buffalo, NY 
k Improved Neubauer Ruling Hemacytometer, American Optical Corp, Buffalo, NJ 
I TDx Gentamicin Assay, Abbott Laboratories, Chicago, IL 
m Hyaluronidase Type I-S; Sigma Chemicals, St. Louis, MO 
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non-weight bearing). Carpal flexion was subjectively assessed by slowly flexing the polymer-treated carpus 
until the horse resisted. When significant resistance in carpal flexion was noted, the lameness score was 
upgraded for I grade at the scale from 0-5. Carpal circumference was measured in centimeters at the level of 
the mid-accessory carpal bone using a flexible tailor's tape. Tarsal joint circumference was measured at the 
level of the polymer-injection site, which was marked by a simple interrupted suture using 2-0 nylon®. 
Statistical analysis 
Paired t test, with a Bonferroni adjustment for the number of comparisons made, was used to 
determine whether statistically differences existed between results from specimens obtained at PIH 0 and from 
all other times within each group. This analysis was used as a variance-stabilizing transformation and was 
performed on the logarithm of the observations. The Wilcoxon signed rank test was performed on the same 
data to verify that results obtained were not reliant on the t test's assumption of an underlying normal 
distribution. The Tukey w procedure, which corrected for subsequent multiple comparisons, was used to 
determine statistically significant differences in gentamicin concentrations between the two polymers. 
Statistical significance was established at p <0.05. 
Results: 
Gentamicin concentrations from PLGA and PCL 
Concentrations resulting from the release of gentamicin from PLGA and POE into synovial fluid over 
the study period reached levels of 2.2 µg/mL and 15.6 µg/mL, respectively, at 24 hours (Table I). The release 
concentrations peaked at 96 hours for the PCL at 59.3 µg/mL and at 2.6 µg/mL at 168 hours for the PLGA. 
Although higher gentamicin release was found with the PCL there was a marked fluctuation in the 
drug concentrations and the release occurred very non-linear. The drug concentrations in the synovial fluid 
from the PLGA microspheres were fairly constant. The nearly constant gentamicin concentration of 
approximately 2 µg/mL was at the MIC (Minimal Inhibitory Concentration) which has been reported for most 
clinical organisms. Bioactivity assays confirmed that the concentration of gentamicin within the synovial fluid 
samples were high enough to inhibit growth of S. aureus. No significant antimicrobial activity was detected in 
the samples from joints without the PLGA. The zones of inhibition for S. aureus growth for PLC and PLGA 
were proportional to the gentamicin concentration measured in the same sample (PCL/PLGA, day 1, 28 mm, 
17mm; day 3, 32 mm, 19 mm; day 5, 25 mm, 15 mm; day 8, 20 mm, 17 mm; day 10, 9 mm, 10 mm, 
respectively). 
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Table 1. Gentamicin elution concentrations from 50/50 PLGA and PCL in synovial fluid in vitro. 
Synovial fluid cy tological findings 
1mes 
(hours) µg/mL µg/mL 
Cytological parameters such as total cell count and protein differed significantly between the PLGA 
and the POE injected joints. 
At PIH 0, synovial flu id specimens from all horses from both groups, POE and PLGA, prior to 
catheter placement and polymer injection had pale yellow to almost white color and ranged from clear to 
cloudy transparency. This changed in the polymer treated joints after 24 hours to a more turbid appearance and 
the control joints remained cloudy throughout the study period. There was no significant change in pH levels 
(pH 7.0) between polymer-treated and control joints at anytime. 
Injection of the PLGA polymer into the joint resulted in a mean WBC count of 28,945 cells/µL with 
91 % mildly degenerated neutrophils versus 8,230 cells/µL and generally well preserved neutrophils in the 
control joints. The greatest increase was observed at PIH 48. This count, however, decreased significantly at 
PIH 72 hours and reached almost levels of the control (catheterized) joints. The mean small mononuclear (SM) 
cell count was high at PIH 24 for both joints; the greatest increase was observed for the catheter-control group 
(13 .33%, PIH 24), but was statistically not significantly different. By PIH 48, the mean SM counts for both 
joints in all horses were similar and reached 2.66% and 4.33% in the PLGA- and control joint by PIH 72, 
respectively. The mean SM counts for the entire study period were 3.92% in the PLGAjoint and 6.92% for the 
control joint. There was a significant difference in the large mononuclear (LM) cell counts between the PLGA 
joint and the control joints. LM counts increased in the control joints (81 %, PIH 24) and maintained elevated 
compared with the PLGAjoint (62%, PIH 24). This difference was particularly significant during PIH 24 
through 72 . 
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Figure 1. Mean Total Leucocyte Count after PLGA injection 
At PIH 96 the difference was not significant anymore and the LM counts for both joints were decreased. The 
mean LM counts for the entire study period for the PLGA joints and the control joints were 28. 75% and 
48.66%, respectively. Few macrophages appeared activated, which was most prominent at 48 hours . 
The mean refractive index of all synovial fluid specimens for the control joints in the PLGA group 
(catheterized, but not polymer-treated) was 1.54 g/dl (range 1.0 g/dl to 2.46 g/dl). One horse (horse 1) out of 
this group had a significantly higher mean index than the two other horses (2.46 g/dl). However, the same 
horse had an overall slightly higher index in the catheterized joint compared with the catheterized and polymer 
treated joint and also had a significantly higher pre-catheter index ( 1.1 g/dl) than the two other horses. The 
mean refractive index in the polymer-treated joint reached 3.48 g/dl. There was a statistically significant 
difference in the index from horse one and the two other horses. The index in horse one ( l . 96) was much lower 
then the average of the two other horses (4.25). 
Figure 2. Mean Total Leucocyte Count after POE injection. 
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Injection of the POE polymer resulted in a mean WBC count of 6,091 cells/µ! with mostly well 
preserved neutrophils. The mean WBC counts in the control joint was 2,588 cells/µ! with well preserved 
neutrophils. The largest increase in total white cells occurred at PIH 24 as seen in the PLGA group, however, 
this increase was not as significant. Total cell counts remained closer at control levels over the rest of the study 
period. The mean refractive index in the control group (sham injected) was 1.23 g/dl versus 1.98 g/dl in the 
POE group. Although the most significant increase occurred again at PIH 24 and remained elevated in both 
groups, this increase was not as significant in the POE group when compared with the PLGA group. 
Table 1. 
1me 
Cell 
type/polymer 
Neutrophils 
Lymphocytes 
Mononuclear 
Eosinophils 
Macrophages 
Picture 1. 
Mean Differential Cell Count of PLG and POE polymer injected joints in comparison. 
NA=Not available 
re- nJeC ion ay ay ay ay 
Day I 
Control: Mononuclear cell prior to PLGA injection. 
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Picture 2. 24 hours post-injection: Predominantly neutrophils with some mononuclear cell. 
Picture 3. 72 hours post-injection: Mixed population of mononuclear cells and neutrophils 
Clinical evaluation 
None of the horse in both groups became lame. There were no significant differences among the 
horses and joints concerning lameness grades (p <0.05). However, there was a trend for increased joint 
circumference in the POE injected joints. Increase in joint circumference could be palpated mainly over the 
dorsal aspect of the carpal joint or as generalized effusion of the tibio-tarsal joint. This joint distension, 
however, did not cause resistance when the joint was flexed. 
There was minimal swelling present at the catheter site while the catheter was in place and after it had 
been pulled. Carpal flexion was not significantly decreased, however, one horse showed some resistance to 
flexion at PIH 24. This response subsided at PIH 36 after the catheter had been pulled and completely resolved 
at PIH 48. Although there was a significant difference in the total cell count and the protein levels between 
both polymers, this difference was clinically not appreciable. 
Discussion: 
Our findings concerning the gentamicin release concentration from PLGA polymers differ from other 
studies. Although previous studies used phosphate buffered saline as the medium the drug eluted into, the 
concentrations in this study were significantly lower from results in other studies(l 1,12). This may have been 
caused by the relatively high viscosity and high concentration of hyaluronan of synovial fluid, which may 
interfere with the erosion process from PLGA polymers. Low molecular weight copolymers such as the 50/50 
DL-PLG can be expected to degrade very rapidly, which is one of the reasons this polymer was chosen for 
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evaluation. The degradation profile will typically show an initial lag time during which diffusion of water 
occurs. We did not observe this characteristic lag time during the study period; however, it might be possible 
that hydrolysis was delayed by the different pH and environment of the synovial fluid. Hydrolysis is also 
affected by the size, hydrophilicity, and crystallinity of the particular polymer and requires consideration when 
designing a drug delivery system. 
Another reason for the low concentrations may have been the gentamicin loading (15%), which may 
not have been high enough to release the desired concentrations. However, higher release concentrations of 
gentamicin with a similar loading have been reported(l3). Clinically, it would be desirable to have higher 
concentrations of drug in the synovial fluid because concentrations l 00 times greater than the MIC for an 
organism may aid in the elimination of infection. 
PCL is an aliphatic high molecular weight homopolymer with a slow degradation rate, which may be 
increased by copolymerization. PCL has a high permeability to many drugs, which provides a rapid release and 
is characteristic for PCL devices(l4). The principle mode of degradation, hydrolysis, does not differ from 
lactide and glycolide polymers. Degradation proceeds first by diffusion of water into the material (initially into 
the more amorphous zones) followed by random hydrolysis, fragmentation of the material, and finally a more 
extensive hydrolysis possibly accompanied by phagocytosis, diffusion, and metabolism. Although the PCL 
exhibited a very random release of gentamicin, concentrations were more desirable clinically. Considering the 
clinical use of aminoglycosides, the release behavior of the PCL may be more advantageous than the constant 
low levels observed with the PLGA. Aminoglycosides have a prolonged "post-antibiotic" effect and are Jess 
nephrotoxic when administered at a high dose in single daily injections(l5). Therefore, the more pulsatile 
release of gentamicin from the PCL may be clinically beneficial. 
Synovial fluid cell parameters were used to establish preliminary clinical data concerning the injection 
of these polymers into synovial cavities. Synovial cell parameters including the WBC are helpful parameters in 
the diagnosis of joint disease (2 l ). Although there is no clear definition what degree of elevation in the WBC 
may indicate traumatic versus infectious arthritis, WBC counts are valuable diagnostic and prognostic tools 
concerning the health of the synovial environment. The WBC of normal equine synovial fluid has been reported 
by different authors as 167 ± 21 and 87 cells/mm3• Neutrophils, lymphocytes and large mononuclear cells are 
observed, but the percentage of the neutrophils is generally Jess than 10% in normal fluids . Quantitative and 
qualitative changes in the leukocytes can provide an indication of the magnitude of synovial membrane 
inflammation. 
PLGA and POE cause a short-term moderate synovitis in the equine joint without significant clinical 
signs. There was a sharp rise in the mean WBC 24 hours after PLGA injection, which reached control levels at 
72 hours. This raise was significantly lower in the POE group compared with the PLGA and the control joint. 
Although no clinical data are available concerning the response of synovial structures to POE or PLGA, clinical 
signs including formation of fibrous tissue, osteolytic reactions and bone resorption have been well documented 
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for PLG and PLGA implants in human medicine. These findings have been more frequently observed at 
around 12 weeks after implantation(l8). A non-specific inflammatory response in these studies was connected 
with the breakdown of the polymer and the accumulation of degradation products. 
Biocompatibility of PLGA polymers has been evaluated for their use as suture material, bone plates, 
implant materials, bone graft substitutes, and nerve graft substitutes(4,5,6,7). Intramuscular administration of 
PLGA microcapsules of various particle sizes in rats evoked a sharply localized acute inflammatory reaction 
followed by minimal connective tissue, macrophages, and foreign body cell response(S). These responses 
declined in parallel with microsphere degradation. A dose dependent effect was observed by Julienne et al. 
following IV injection of PLGA particles in mice(9). At a level of 665 mg/kg, microspheres were well 
tolerated, whereas at 1000 mg/kg, 20% of the mice died from cyanosis. Although tissue responses from PLGA 
and PGA implants are generally considered mild without adverse immunological and toxicological effects, 
significant inflammatory responses have been observed. PGLA polymers were tested as strips deployed 
longitudinally across 90° of the circumferential surface of coil wire stents and implanted in porcine coronary 
arteries of2.5- to 3.0 mm diameter( IO). Stent patency was assessed by angiography followed by microscopic 
examination of the coronary arteries. Multinucleated giant cells and microphages surrounded by proteinaceous 
debris were observed at the interface between polymer and tissue. Signs of acute inflammation included the 
presence of granulocytes (mainly eosinophils), lymphocytes, and occasional plasma cells at the site of the 
polymer strips. It was concluded that the marked inflammatory reaction within the coronary artery had not 
been expected on the basis of in vitro tests and may be attributable to a combination of parent polymer 
compounds, biodegradation products, and possible implant geometry. 
In contrast, poly(lactic acid) polymers have been evaluated by several investigators as carriers of 
antibiotics for the treatment of osteomyelitis. In one study, implants consisting of pure poly(L-lactic acid) (L-
PLA), copoly(DL-lactic-co-glycolic acid) and 20% poly(DL-lactic acid) (DL-PLA) impregnated with 
gentamicin were placed subcutaneously into the back of rats just lateral to the mid line( 11 ). During the first 24 
hours L-PLA and DL-lactic acid-glycolic acid copolymer implants released a total amount of 3600 µg/ml and 
1900 µg/ml gentamicin, respectively. Very good tissue compatibility was found based on the absence of an 
inflammatory reaction throughout the entire time of implantation as shown by microscopic examination. 
Histologically, a typical foreign-body reaction was seen with abundant macrophages and 
multinucleated foreign-body giant cells after polymer injection. We observed few macrophages, but our study 
period covered only an initial time period. Long term evaluation may reveal a different cytologic picture. 
Also, the amount of polymer injected into the joint may play a significant role concerning the magnitude of the 
cytologic response. 
The lymphocyte count was consistently higher in the control joints of two horses and was higher in the 
PLGA joint of the third horse. The greatest difference occurred at PIH 24 in two horses of the PLGA group 
and then subsided to non-significant levels. The mononuclear cell count was elevated only in the control joint 
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of one horse in this group, which had also a significantly elevated lymphocyte count in the control joint. There 
was a profound mononuclear cell response in the POE injected joints compared with the PLGA group. Also, 
the lymphocyte count was consistently higher in the POE group than in the PLGA group. Because the POE has 
never been evaluated for the use in synovial structures such as the joint only limited biocompatibility data is 
available for older, second generation, POEs. Previous studies in rabbits revealed a strong eosinophilic reaction 
with densely packed lymphocytes after subconjunctival injection. A 200 µI sample of POE was injected into the 
subconjunctival nasally to the superior rectus muscle. Daily clinical observations were performed and tissue 
blebs were identified. On histologic evaluation eosinophils were the most frequent type of inflammatory cells 
at three days. At ten days, fibroblasts were the predominant cell type at the site of injection and the POE had 
degraded. This significantly differs from our study, which did not show a significant contribution of eosinophils 
to the tissue response. The study further concluded that purification technique improves the biocompatibility. 
Therefore, it may be the amount of polymer injected, the degree of POE purification and the site of injection 
that ultimately may dictate the type of cell response to the POE. 
Catheterization caused a mild inflammatory response of the synovium in the control joint as seen in 
previous studies ( 16). The swelling over the dorsal aspect of the carpal joints and increase in joint 
circumference can at least in part be attributed to the repeated intra-articular injections after the catheter was 
pulled. Harvesting of synovial fluid via repeated arthrocentesis does by itself cause some degree of 
inflammation and may have attributed to the elevation in cell counts. We experienced difficulties in 
maintaining catheter patency and decided to remove the catheter at PIH 36. Because arthrocentesis was 
performed using the dorsal joint pouch, the swelling was localized to that site of the joint. A similar 
observation was made in the POE injected joints. Swelling mainly occurred at the site of arthrocentesis, which 
was in the medial and lateral pouch of the tibio-tarsaljoint. 
Although there was a significant raise in the WBC in the PLGA injected joints, none of the horses 
became significantly lame. The mild joint effusion and reduced carpal flexion resolved clinically in all joints 
after 8-10 days. 
In summary, the PLGA showed acceptable biocompatibility in vivo, but did not release gentamicin in 
clinically relevant concentrations in vivo and showed poor elution characteristics compared with the PCL. 
Polycaprolactones deserve further evaluation in vivo, because they released high gentamicin concentrations in 
vitro and exhibited random release kinetics. The POE on the other hand proved to be Jess irritating to the 
synovial membrane compared with the PLGA but did also not provide enough drug within the joint to be of 
clinical significance. Because the preliminary results of this study may only be applicable to the specific 
polymers investigated, biocompatibility and drug elution from the polymers may change with altering 
molecular weight, polymerization catalysts, plasticizers, and glycolic unit content. Any future studies 
developing an effective drug delivery system will have to take into account drug elimination rate of the 
synovial membrane. 
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CHAPTER 4. GENERAL CONCLUSIONS 
The research presented in this thesis establishes the groundwork for further investigation into the use 
of biodegradable materials as drug carriers for the treatment of infectious musculoskeletal conditions in the 
horse. Sustained local drug delivery is becoming the route of choice for a large number of therapeutic agents 
and will significantly re-shape drug administration in companion animals and humans in the future. 
We were able to show that the antibiotic-impregnated poly(ortho ester) can rapidly eliminate infection 
from a cell culture system and maintain cell function as indicated by normal HA-concentrations. However, one 
of the most important findings in our study was that although infection is eliminated, ongoing detrimental 
changes occur. This was indicated by the rapid decline of HA-concentration in our cell cultures post-infection 
and emphasizes that (I) any infection may potentially cause chronic damage and (2) antimicrobial therapy as 
the only treatment will not prevent or decrease these ongoing changes. One surprising finding of our in vitro 
study was the fact that the POE appeared to cause more changes in the cartilage cultures versus the synovial cell 
cultures. This will require more investigation particularly concerning the long-term outcome of joint infections. 
Any local drug delivery will need to also address the inflammatory component, which is triggered by the 
microorganisms. Our findings suggest that a locally delivered combination treatment based on antibiotics and 
anti-inflammatory drugs may, in fact, be of high value. 
We were unable to reproduce the high gentamicin concentrations of the diffusion chamber and the cell 
cultures in our in vivo study. This supports previous evidence of other studies that in vivo results may greatly 
differ from in vitro findings. Although one of our objectives was to find out whether or not the polymer 
material would damage synovial structures, the complex nature and environment of a joint cannot be imitated 
or reproduced in the laboratory. It can only be speculated at this time why we did not find any clinically 
significant drug levels in the POE and PLGA injected joints in the in vivo study. One possible reason may be 
that our immunfluorescence assay to measure gentamicin concentrations may not work accurately. Although 
TDx has been used in previous studies to determine gentamicin levels in synovial fluid this assay procedure has 
not been validated for drug monitoring in synovial fluid. 
Another reason, which may be responsible for the low concentrations, may be the tremendous ability 
of the horse joint to eliminate gentamicin from the synovial space. The rate and amount of drug elimination by 
the joint space by far overcomes the amount of drug and release rate from the polymer. Previous joint studies 
showed that the elimination half-life (t.v2) of gentamicin in synovial fluid is approximately 260 minutes and the 
clearance approaches 1.22 mL/min. If one considers a therapeutic drug concentration of approximately 100 
µg/mL maintained for a seven day treatment period in the synovial space, then approximately 1.22 gr of 
gentamicin would be necessary to incorporate into the POE. In order to reduce this dose, combination therapy 
consisting of intrasynovial and systemic drug administration may be a clinical alternative. Previous studies 
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indicated that the highest drug concentration in the synovial fluid was found when systemic drug therapy was 
added to intra-articular administration of gentamicin( 16). 
Our in vivo observations confirm that cell cultures do have significant limitations and results should be 
cautiously interpreted. This accounts in particular for our findings in the toxicity study. However, the results 
of our studies were encouraging in that none of the polymer materials investigated in vitro and in vivo resulted 
in acute or chronic detrimental tissue changes, which would prohibit their further investigation as drug delivery 
carriers. In fact, the observed side effects after injection of the polymer into a joint does not seem to outweigh 
the benefits of a sustained drug release system at this point. 
Much of the initial and ongoing work in this project involved the development of an injectible 
material. We experienced significant problems in formulating a polymer solution (PLGA) or ointment (POE), 
which could be injected through a commonly used needle size (14 ga) into the joint. Preliminary work with the 
POE resulted in a more viscous form and showed that warming up of the material prior to injection significantly 
facilitates handling. Although improvements in the "compounding" of the PLGA were made and the 
"injectability" improved, this still requires additional work. 
One aspect of the PLGA microspheres that deserves some notice is the fairly easy (but time 
consuming) production of this form of drug delivery device. Considering that the equine practitioner is already 
routinely making and using PMMA beads, the "home-cooking" of a PLGA-based biodegradable sustained drug 
delivery device for implantation into surgical sites may become possible in the near future. 
Although our initial experiences with the PLGA and PCL in clinical case management was somewhat 
mixed (see case studies Appendix A) the findings of our study may open a new field of opportunities to combat 
infection. Future studies which may involve the controlled pulsatile release of aminoglycosides within a joint, 
the efficacy of an sustained drug delivery system in the treatment of horses presented with naturally occurring 
septic arthritis, synovitis and/or tenosynovitis, and the incorporation of other drugs such as anti-inflammatories 
will further elaborate the efficacy of local drug release technology in horses. 
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APPENDIX A. SUPPLEMENTAL MATERIALS AND METHODS 
Preliminary equine-related studies with the POE 
In order to detennine whether or not the POE is tolerated within a synovial cavity and what 
degree of inflammation can be expected, a sample ofpoly(ortho ester) was injected into the right tibiotarsal 
joint of a two year old female Quarterhorse. The horse was examined prior to injection to make sure no 
underlying orthopedic disease was present. A thorough lameness exam was perfonned including flexion-tests 
of both rear limbs. No lameness was detected. 
The polymer consisted of a sample of 10 ml poly( ortho ester) (Lot 499-50) delivered in a 12 cc syringe 
with a biodegradation of7-10 days. The sample was sterilized by the linear accelerator facility using gamma-
irradiation (2.5 mrad). 
On day one, the right tibiotarsal joint was aseptically prepared for arthrocentesis. A 14 ga. l l /2 " 
needle was entered into the joint under sterile conditions. Prior to injecting the sample (=10 cc), a synovial 
fluid sample was taken and put into an EDT A-tube for analysis. The sample was than injected through the same 
needle (14 1112") and the horse closely observed for any signs of discomfort. 
The pre-injection synovial fluid sample was submitted for cytology. The analysis was consistent with 
nonnal synovial fluid. On day two, arthrocentesis was repeated and the synovial fluid sample analyzed for 
cytology. Results were consistent with a mild inflammatory response. Total cell count went up to 8,060/µl , 
there were 70% macrophages, 20% non-degenerated neutrophils and no lymphocytes seen. 
On day six, a second post-POE synovial sample was taken and analyzed for cytology. Results showed 
a decrease in Total Cell Count ( 1,270/µl) and a nonnal cell-type distribution. During the trial period, the horse 
never became lame or appeared sore on palpation of the joint. However, there was a mild increase in joint 
distension noted which completely resolved over a ten day period. These very preliminary results encouraged 
us to pursue the POE as a drug delivery system and resulted in a research collaboration between Advanced 
Polymer Systems, Redwood City, CA, and Iowa State University. 
Collection of synovial fluid from euthanatized horses 
Synovial fluid was collected from horses euthanized for reasons other than musculoskeletal disease. 
Because of the size of the joint space and available amount, the tibio-tarsal, radio-carpal, and metacarpo-
phalangeal joints were used to collect synovial fluid. All joints were aseptically prepared prior to 
arthrocentesis. An 18 ga 11/2 inch needle was used to collect fluid into EDT A tubes. The tubes were 
immediately frozen to -60°C until used for the in vitro elution studies. Because there was a concern that 
synovial fluid kept in EDT A tubes may by itself inhibit the growth of S. aureus, culture studies were perfonned 
prior to the bioactivity testing of the in vitro elution study involving the PLGA and PCL polymers. Mueller-
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Hinton agar plates were inoculated with a S. aureus and 5 mm holes were punched into the agar. The holes 
were filled with 100 µl of EDT A synovial fluid and incubated for 24 hours at 37°C. The plates were evaluated 
after 24 hours and no zone of inhibition could be observed. 
Preliminary in vitro elution characteristics POE/gentamicin 
The in vitro release kinetics of gentamicin sulfate from the POE polymer was performed using two 
double diffusion chambers separated by a Millipore membraneb. Both chambers were filled with a total of20 
ml of sterile equine synovial fluid, which was harvested from horses euthanized for reasons other than 
musculoskeletal disease. The synovial fluid was collected in sterile heparinized EDTA tubesd and frozen (-60° 
C) until used for the experiment. The donor side contained a 500 mg sample of POE loaded with 5% 
gentamicin sulfate, and the receiver side contained synovial fluid only. The chamber was continuously agitated 
on a shaker at room temperature, and 0.5 ml samples of synovial fluid from the receiver side were collected and 
replaced with fresh synovial fluid at 12 and 24 hours and then daily for a total of 14 days. 
Drug levels in the collected samples from both chambers were quantified using an automated 
fluorescence polarization Immunoassay (FPIA) analyzerc. Hyaluronidase lyophilized desiccatee was added to 
each sample to decrease the viscosity of the synovial fluid for analysis by the TDx-analyzer. 
Pharmacokinetic studies commonly use buffer systems such as PBS (pH 7.3, 154 mmol/L) to 
determine the concentrations of drug released into a closed system (34). An estimate of polymer volume needed 
to provide therapeutic drug concentration (eg. 2-4 µg/mL) within the synovial space is difficult. In general, for 
the in vitro kinetics the amount of synovial fluid in the chamber must be large enough so that after 24 hours 
release, the synovial fluid is less than 10% saturated. This is known as infinite sink conditions which differs 
from the joint because drug is released into a finite space in the joint. Therefore, infinite sink conditions may 
not be representative of the in vivo situation. 
However, we encountered problems with the in vitro kinetic set up. While we found that the release of 
gentamicin from the POE within the first 24 hours was almost linear, a burst of drug release occurred after that. 
Gentamicin concentration peaked at 96 hours (6500 µg/mL) and adjusted then at around 3100 µg/mL for the 
rest of the study period. This phenomena has been well recognized in the synthesis of polymers and constitutes 
one of the greatest problems in the design of controlled drug delivery systems. "Dumping" of the incorporated 
drug may lead to undesired toxicity of the drug and makes the release kinetics much more random. Ideally, the 
main mechanism responsible for the release of drug from a biodegradable polymer is surface erosion while the 
drug is uniformly distributed through the polymer facilitating zero-kinetic release(28). In order to obtain zero-
order release a geometry, may be necessary that does not change its surface area as a function oftime(29). 
Bulk erosion, in addition to surface erosion, as seen in both the kinetic- and the culture study, is a result of the 
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polymer imbibing water into the center of the matrix and has been observed with other polymers as well. 
Polylactic acid (PLG) and polyglycolic acid (PLGA) polymers used for biomedical application are well known 
for this problem which makes the controlled release in these materials particularly difficult(30,3 l). 
Another problem we observed with the in vitro kinetic study was the fact that we found more drug 
than we could account for when considering the total amount of gentamicin in the POE sample. Although 
technically the 500 mg sample of POE contained not more than 25,000 µg total gentamicin (5 weight%), we 
found approximately 84,000 µg represented in the synovial fluid solution. Several circumstances may help 
explaining this discrepancy. First, we could have used more polymer than we initially weighed out. Second, the 
amount of gentamicin incorporated into the polymer during fabrication was more than 5%, and thirdly, our 
immunofluorescence assay (TDx) may not work accurately. One of the first things to make sure will be to 
evaluate the accuracy of the assay by measuring gentamicin concentrations in synovial fluid using High 
Pressure Liquid Chromatography (HPLC). 
Figure 1. Preliminary gentamicin kinetics from POE polymer (5 wo/o gentamicin) in diffusion chamber 
Infection of synovial membrane for the POE efficacy study 
Synovial explants were infected with a S. aureus, which had been previously harvested from an 
infected joint and frozen at -70°C until use. Each inoculum consisted of 3 mL of standard medium that 
contained 135 colony-forming-units (CFU)/mL of S. aureus, for a total bacterial inoculum of 405 CFU. This 
number was selected based on previous studies of infected equine synovial explants. An inoculum of 150 
CFU/mL was visually estimated by matching sample turbidity to a 0.5 McFarland turbidity standard (BBL, 
Becton Dickinson Microbiology Systems, Cockeysville, MD). The exact number of CFU/mL was determined 
by plating 10 µL of the stock solution on Mueller-Hinton agar plates and overnight incubation at 37°C. The 
mean number of final, viable CFU/mL was 135. After inoculation, explants were incubated for 18 hours, then 
infected medium was removed and replaced with fresh standard medium. 
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Making of microspheres: 
Microspheres were made using the emulsification-solvent evaporation technique. This technique was 
first described by Beck et al. (1979) and is the most widely used manufacturing technique for biodegradable 
microspheres. Microsphere formation consists essentially of three stages: (I) droplet formation, (2) droplet 
stabilization, and (3) microsphere hardening. 
First, a dispersed phase containing the polymer is emulsified in an immiscible continuous phase 
containing a stabilizing agent. The second stage involves the diffusion of the solvent from the emulsion droplet 
into the continuous phase and its subsequent evaporation. Selection of an appropriate organic solvent for the 
disperse phase may mainly depend on toxicity, immiscibility with the continuous phase, and drug solubility. 
One of the most widely used organic solvents, and used in our laboratory for this purpose, is methylene 
chloride. In order to stabilize the dispersed-phase droplets, which are being formed during emulsification, the 
use of a surfactant is necessary. Surfactants are amphipathic in nature and hence will align themselves at the 
droplet surface. Polyvinyl alcohol (PVA) is by far the most widely used surfactant and appears to be the most 
effective for formation of particles below l µmin diameter. 
The mixing conditions (eg. stirring, sonication) primarily influence the size of the droplets and hence, 
the final microsphere size. By increasing the emulsification speed, there is both a decrease in the particle size 
and a narrowing of the size distribution. Following emulsification, the removal ofremnant solvent and 
complete microsphere hardening is accomplished by gentle agitation of the suspension by magnetic stirring at 
room temperature and pressure. This step is of great importance because of toxicological concerns. Incomplete 
removal of solvent from the microspheres may result in tissue irritation unrelated to the microspheres 
themselves and give a false result concerning the biocompatibility of the polymer. Therefore, this process is 
typically followed by a further cleaning process in which particles are washed several times with distilled water. 
After decanting, the microspheres are left behind and undergo the final step of dry freezing. This 
requires typically 24-36 hours and is done under vacuum. 
The following is a protocol, which was used in our study for the majority of the microsphere production: 
1. One gram polymer rods are dissolved in 5 ml methylene chloride. Shake as needed. 
2. Five ml of methylene chloride are added with 150 mg of gentamicin sulfate (100 mg/ml), which results in a 
15 % (weight percentage) drug concentration of the polymer. 
3. The solution is ultrasounded for approximately 40-50 seconds until the solution is white with no flakes. 
4. One hundred fifty ml of l % PVA (grade 70-06, MW 17,600) is added to the solution and homogenized for 
approximately 35-40 seconds to get an approximate microsphere size of 80-140 µm. 
5. The solution is stirred at room temperature for two hours at moderate speed. To determine the size of the 
microspheres, a sample is put on a slide and examined under the microscope at 40x. 
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6. After two hours of stirring, the solution is divided up into 60 ml centrifuge tubes and centrifuged at 1500 
rpm for five minutes. After that, the liquid is decanted and deionized water added. The tubes are shaken 
several times and centrifuged again. This step is repeated for a total of three times for each tube. Then, the 
tubes are sealed and dry-frozen under vacuums for 36 hours using a lyophilizer. 
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APPENDIX B. CASE STUDIES 
Case 1 (ISU# 269175): 6 week old foal with open comminuted MT III midshaft fracture 
A three months old male Quarterhorse foal was presented to the Veterinary Teaching Hospital for an 
open comminuted fracture of the left rear leg. The fracture site was moderately contaminated. The foal was 
put under general anesthesia and the wound thoroughly cleaned. 50/50 PLGA microspheres impregnated with 
15 w% gentamicin were implanted subcutaneously into and around the fracture site. A transfixation cast was 
applied to provide stabilization. The foal recovered uneventful from anesthesia and appeared very comfortably 
weight bearing postoperatively. 
The cast was changed two and a half weeks later which revealed a moderate amount of drainage from 
the fracture site. There was radiographic evidence of sequestra formation. Several small sequestra were 
removed and the wound thoroughly cleaned. A cancellous bone graft from the tuber coxae was harvested and 
put into the fracture site. No residual polymer was seen at that time and more PLGA polymer was implanted. 
The limb was recasted. The foal continued to bear weight on the limb and appeared comfortable. 
Two weeks later the cast was changed again and another large bone sequestrum was removed. 
Drainage had decreased in the amount, however, there was little radiographic evidence for new bone formation 
at the fracture site. Because the foal was clinically doing well, the decision was made to continue and to repeat 
the cancellous bone graft. No further polymer was implanted at that time. A new cast was applied. 
After three more weeks, the foal returned for another cast removal. It had been doing well concerning 
weight bearing on the cast and remained active. The foal had gained weight over the past weeks. The cast 
removal revealed that there was no active infection present. No significant drainage was found at the fracture 
site. The skin appeared to have healed over the fracture. However, there was no significant new bone 
formation radiographically and clinically. The fracture site remained unstable. There were radiographic signs 
of osteoporosis involving the distal aspect of the limb. A new cast was applied. Five days after the new cast, 
the foal appeared significantly more uncomfortable and was spending the majority of the time laying down. 
Because of this sudden deterioration, the cast was removed to inspect the limb. This showed that the skin of the 
site of the fracture had broken open and a significant amount of drainage and pus was present. Because of the 
grave prognosis, the foal was euthanized. 
Case 2 (ISU# 269029): 6 week old calf with open MT III fracture 
A four month old female Shorthorn calf was presented to the Veterinary Teaching Hospital for an open 
midshaft fracture of the right hind metatarsus. The fracture site had been cleaned and debrided and an external 
fixator was applied to provide stabilization. 
Two weeks after the initial treatment, the open fracture site continued to drain moderate amounts of 
pus and debris. Radiographic evaluation revealed few small sequestra at the fracture site. The external fixator 
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was removed and the wound again cleaned and thoroughly debrided. 50/50 PLGA microspheres impregnated 
with gentamicin (40 w%) and 75/15 PLGA microspheres impregnated with Potassium Penicillin (15 w%) were 
implanted into the open fracture site and a cast applied to the limb. Cast removal three weeks later showed that 
drainage had significantly decreased and a soft tissue callus had fonned. 
Case 3 (ISU# 268754): 6 year old female alpaca with severe mandibular actinomycosis 
A two year old female alpaca was presented to ISU for advanced mandibular osteomyelitis due to 
previously cultured Actinomyces bovis ("Lumpy Jaw") and Fusobacterium necrophorum. There was 
significant drainage and thickening at the right mandible. The infection had resulted in a pathologic fracture at 
the rostral aspect of the right mandible. At the time of presentation, the alpaca was able to eat but had lost a 
significant amount of weight. Although the prognosis for long-tenn survival was poor, the owner decided to 
initiate treatment because the alpaca was pregnant. The goal of therapy at this time was to halt the infection 
long enough to have the alpaca deliver the cria. Surgical curettage and debridement was performed and a type 
I Kirschner-Ehmer frame applied on the right mandible to stabilize the jaw. At the same time, small 1.5 mm 
large holes were drilled into the site of the infection. The holes were filled with microspheres of 85/I 5 PLGA 
impregnated with 20 w% Potassium Penicillin or 50150 PLGA impregnated with 20 w% Ceftiofur (Naxel®). 
These antibiotics were chosen based on C&S results. Postoperatively, the alpaca appeared comfortable and was 
eating. She was put on broad-spectrum antibiotics because additional cultures had revealed heavy mixed 
growth of E. coli, Klebsiella, Bacteroides spp. and Streptomyces sp. 
Five weeks later the alpaca was presented again. Radiographic evaluation at that time showed that 
there was no further bone lysis. The KE apparatus was still tight and providing stability to the jaw. The alpaca 
was again anesthetized and the polymer implantation was repeated using the same microspheres and a 50/50 
PLGA impregnated with 40 w% gentamicin. Because the microspheres were difficult to inject into the holes 
using 14 gauge needles, polyethylene glycol (PEG) was added to increase viscosity. This slightly improved the 
injection technique. A transabdominal ultrasound examination was done which confinned that the alpaca 
maintained its pregnancy. She was scheduled for another recheck exam in four weeks. 
Nine weeks after the first PLGA microsphere implantation, radiographs of her mandible showed that 
new bone was filling in the osteolytic areas. The alpaca was doing well, very active and had maintained its 
weight. The KE apparatus was removed and a bone biopsy taken for culture. This revealed no growth on direct 
or enrichment cultures, aerobic and anaerobic. 
Six weeks later the alpaca was still doing well, however, she continued to have a chronic draining tract 
at her right mandible. Culture revealed an Actinomyces species other than A. bovis. 
Four months later the alpaca was represented for recurrence of swelling at her jaw and increased 
drainage. She was still eating, but had not gained significant weight during her pregnancy. Radiographs 
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showed that there was considerable bone lysis consistent with a recurrence of osteomyelitis in her mandible. 
Shortly after, the alpaca delivered the cria and was then euthanized for humane reasons. 
Table 1. Jn vitro gentamicin elution from 500 mg POE (5 w% gentamcin) in synovial fluid 
Collection times Chamber 1 Chamber 2 Mean gentamicin 
µg/mL µg/mL concentration (hours) µg/mL 
6 62 71 66.5 
12 76 135 105.5 
24 115 289 202 
48 4700 2960 3830 
72 5040 6800 5920 
96 6720 6280 6500 
120 4050 2920 3485 
144 3800 3350 3575 
168 3800 3440 3620 
192 3610 3400 3505 
216 3940 3070 3505 
240 2580 2980 2780 
244 4160 3140 3685 
268 3910 3080 3495 
292 4070 3090 3580 
316 4480 3120 3800 
340 4740 3700 4220 
